var title_f25_30_26080="Shoulder axillary view";
var content_f25_30_26080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Axillary view of shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axillary view is taken with the radiograph plate placed on the patients shoulder and the x-ray beam projected through the axilla to the plate. The patient's arm need not be abducted 90&deg;, as this position causes pain. About 10 to 15&deg; of abduction, or just enough to get the x-ray tube between the patient's arm and hip, is usually sufficient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26080=[""].join("\n");
var outline_f25_30_26080=null;
var title_f25_30_26081="Use of nasal reservoir cannula";
var content_f25_30_26081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Use of nasal reservoir cannula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: During exhalation, the membrane in the Oxymizer reservoir cannula&nbsp;is thrust forward, creating a 20 mL chamber. Bottom panel: When the patient is ready to inhale, he/she receives the stored oxygen in addition to the supply oxygen. This allows the patient to become adequately oxygenated at lower supply flows.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26081=[""].join("\n");
var outline_f25_30_26081=null;
var title_f25_30_26082="TEE mechanical mitral valve vegetations";
var content_f25_30_26082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/74517/prmvendt_conv.mp4?title=TEE+mechanical+mitral+valve+vegetations\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram (TEE) of a mechanical mitral valve prosthesis with vegetations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows multiple hazy echos on the prosthetic mitral valve compatible with vegetations from endocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26082=[""].join("\n");
var outline_f25_30_26082=null;
var title_f25_30_26083="Butenafine: Patient drug information";
var content_f25_30_26083=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Butenafine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/61/31699?source=see_link\">",
"     see \"Butenafine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotrimin&reg; ultra&trade; [OTC];",
"     </li>",
"     <li>",
"      Mentax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to butenafine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11573 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26083=[""].join("\n");
var outline_f25_30_26083=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143754\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012768\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012767\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012772\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012773\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012775\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012770\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012771\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012776\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012777\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/61/31699?source=related_link\">",
"      Butenafine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_30_26084="Crystal structure of the abacavir MHC peptide complex";
var content_f25_30_26084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Crystal structure of the abacavir&ndash;MHC&ndash;peptide complex solved to a resolution limit of 2.0",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Diagram of HLA-B*57:01 in gray. The peptide HSITYLLPV is shown in cyan carbons. Abacavir is shown as spheres: orange for carbon, blue for nitrogen and red for oxygen. (B) Drug binding influences the peptide backbone conformation by shifting the main chain. Peptide bound to abacavir and HLA-B*57:01 is shown in cyan. Peptide bound in the absence of abacavir is shown in yellow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ostrov DA, Grant BJ, Pompeu YA, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA 2012; 109:9959. Copyright &copy; 2012 National Academy of Sciences. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26084=[""].join("\n");
var outline_f25_30_26084=null;
var title_f25_30_26085="Large cyst imaged on breast MRI";
var content_f25_30_26085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Large cyst imaged on breast MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The T2 weighted image (A) shows a T2 bright mass in the central right breast (red arrow). The T1 weighted fat saturated pre-contrast image (B) shows a T1 hypointense signal (yellow arrow) and on the post contrast image, there is no enhancement (C). These findings are characteristic of a cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26085=[""].join("\n");
var outline_f25_30_26085=null;
var title_f25_30_26086="CPR position PI";
var content_f25_30_26086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    CPR position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 707px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressing on the chest for CPR is called doing \"compressions.\" To do compressions, make sure the victim is on a flat, solid surface. Then kneel over the victim, stack your hands on top of one another with both palms facing down, and lock your fingers together. Holding your arms straight, press on the center of the victim's chest with the heel of your bottom hand. Use your body weight, rather than the strength of your arms, to press on the chest. Make sure the victim's chest drops down at least 2 inches under your weight with each push. Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26086=[""].join("\n");
var outline_f25_30_26086=null;
var title_f25_30_26087="A short primer on cost-effectiveness analysis";
var content_f25_30_26087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   A short primer on cost-effectiveness analysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26087/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26087/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26087/contributors\">",
"     John B Wong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26087/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26087/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26087/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/30/26087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare advances such as new drugs, devices, or screening and diagnostic tests must demonstrate safety and efficacy to be approved for clinical use. However, because of rising healthcare costs and limited budgets, questions may remain about their value [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/1\">",
"     1",
"    </a>",
"    ]. Cost-effectiveness analysis is one approach to determining value and refers to a method for assessing the costs and health benefits of an intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/1\">",
"     1",
"    </a>",
"    ]. Assuming that health budgets cannot meet all of the possible demand, cost-effectiveness evaluation can assist decision-makers in allocating resources to maximize the net public health benefit when choosing among options in the care of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cost-effectiveness analysis has become a fundamental research method in health and medicine, it also has great potential to be misunderstood because of methodological complexity in definitions, measurement, and interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/8\">",
"     8",
"    </a>",
"    ]. The term \"cost-effective\" itself is frequently misused as an adjective (eg, an intervention is \"cost-effective\") without providing a point of reference.",
"   </p>",
"   <p>",
"    This topic review will provide a basic overview of the principles of cost-effectiveness analysis while highlighting some of the controversies. Detailed discussions on this topic have been presented in a series of consensus statements issued by the Panel on Cost-Effectiveness in Health and Medicine through the United States Public Health Service [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four types of economic analysis have been applied to health care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cost-effectiveness analysis or",
"      <strong>",
"       cost-utility analysis",
"      </strong>",
"      (a type of cost-effectiveness analysis) is most commonly used for performing economic analyses in healthcare. In these analyses, monetary and health outcomes are measured separately and the relative value of an intervention is measured as the additional cost to achieve an incremental health benefit such as dollars to prevent a case of cancer. In cost-utility analysis, the effectiveness metric becomes life expectancy adjusted for the morbidity or quality of life associated with the alternative strategies.",
"      <br/>",
"      <br/>",
"      Four outcomes are possible when comparing two alternatives (such as screening versus no screening) using cost-effectiveness analysis: screening is either more expensive or less costly than no screening and in either case it may improve or worsen health outcomes. If no screening costs more and leads to worse outcomes, screening is cost-saving and is preferred to no screening because it improves health outcomes at a lower cost. The situation is more complex if screening costs more but also leads to health benefits, in which case the cost-effectiveness of screening can be determined [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/4\">",
"       4",
"      </a>",
"      ]. Cost-effectiveness does not necessarily imply that an intervention is cost saving. Similarly, an intervention cannot be considered to be cost-effective merely because it is more effective.",
"     </li>",
"     <li>",
"      Cost-identification or cost-minimization analysis simply examines costs of care, implicitly assuming equal health benefits for all of the alternative options and thus ignoring non-economic outcomes.",
"     </li>",
"     <li>",
"      Cost-benefit analysis incorporates both costs and health outcomes, placing a monetary value on health outcomes so that the alternatives can be evaluated on a single outcome measure. However, because assigning a monetary value to a health outcome (or life) raises many ethical objections, cost-benefit analysis has generally not been accepted in healthcare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The point of view of the analysis determines which costs and health effects are considered. As an example, patients, providers, health payers, and society may view antibiotic costs differently: patients may consider only out of pocket or co-payment costs; health payers may consider the antibiotic cost and whether it is generic or non-generic; and society may also consider the costs of emerging drug resistance from antibiotic overuse. Providers may consider the health benefit for an individual patient but weigh it against the public health implications of antibiotic overuse.",
"   </p>",
"   <p>",
"    Cost-effectiveness analyses ideally apply a societal perspective to include costs, benefits, and harms that may extend beyond the payer or provider directly involved in the decision [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/2\">",
"     2",
"    </a>",
"    ]. The societal perspective represents the overall public interest by including social opportunity costs where the use of limited resources (such as personnel, hospital beds, donor organs, or budgets) results in the loss of opportunity to use those funds (or resources) for other purposes. The societal perspective allows cost-effectiveness results to be compared directly with other interventions from a public health vantage point [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Costs refer to the total net expenditures related to an intervention, including the costs of treatment, adverse treatment effects, and future possible savings from the prevention of disease or morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/1\">",
"     1",
"    </a>",
"    ]. Costs are distinct from charges (which include a profit margin). They can be categorized as [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct medical care (eg, physician time, test, or drug)",
"     </li>",
"     <li>",
"      Direct nonmedical care (eg, food, transportation, lodging, clothing, home aides, care by family members due to illness)",
"     </li>",
"     <li>",
"      Time or indirect morbidity and mortality (eg, lost productivity from missed work or loss of life), and intangible (eg, pain and suffering).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fixed costs are those unrelated to short-term changes in volume (eg, the cost of an endoscope) while variable costs are those directly related to changes in volume (eg, the cost of stool guaiac cards) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimation of costs can be done from a top-down or a bottom-up approach and can be retrospective or prospective. In a top-down analysis, an appropriate clinical cohort is identified, and their aggregated economic or resource costs are obtained from patient specific medical billing data usually as charges (eg, hospital or physician bills), which are then adjusted with cost to charge ratios. In a bottom-up approach, estimates are obtained in a two-step process. First, the frequency of utilization of individual resources is obtained (eg, drugs, tests, procedures, and hospital days). Subsequently, the frequencies are multiplied by each unit's cost and then summed to yield a total cost. A complete assessment of costs may also involve \"microcosting\" in which additional costs such as the contribution of nursing care, supplies, or ancillary services to specific costs (such as a hospital day) are detailed. Not surprisingly, the method used to determine costs can result in substantially different estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practice patterns and costs may vary considerably across different providers or regions. This difficulty can in part be addressed by estimating average costs and ranges and by performing sensitivity analysis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Sensitivity analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effectiveness is typically measured in units that are relevant to the condition under study and are meaningful for the decision-maker. Examples include cancers prevented, lives saved, or life years gained. A standard outcome scale allows policy makers to compare the relative net health benefits of alternative funding decisions. Thus cost-utility analysis frequently uses quality-adjusted life years (QALYs) gained to reflect not only prolongation of life but also the quality of life associated with those years (eg, surviving without prostate cancer but with impotence from its treatment).",
"   </p>",
"   <p>",
"    To determine quality of life, utility assessment involves the quantification of preferences for health outcomes. Although methods to determine health effects and to incorporate quality of life have not been standardized, the following approaches have most commonly been used to address these issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"time trade-off\" and \"standard gamble\" methods [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/13\">",
"       13",
"      </a>",
"      ]. In the former method, individuals choose between living a shortened amount of time with perfect health and living longer with impaired health. The length of time is varied until the individual has difficulty deciding between the alternatives. If someone were indifferent to \"living six months of life in perfect health versus living for one year with hepatocellular carcinoma,\" then living a year with hepatocellular carcinoma equals living six quality-adjusted life months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the latter approach, individuals choose between a guaranteed intermediate health outcome and a chance of having either the worst outcome (most often death) or the best outcome. The likelihood of dying is varied until individuals have difficulty choosing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scales that tabulate pre-measured preferences for health states or outcomes defined in various dimensions (such as the Health Utilities Index, the Quality of Well-Being Scale or EuroQOL) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Besides variation in the methods to assess \"utilities\" or \"preferences,\" the study population used to determine quality of life affects the estimate. Different estimates may be reached depending upon whether the study population included physicians, patients with the disease, or individuals from the general population who have not experienced the disease. As a general rule, individuals experienced with a disability assign a higher (better) quality of life value than those from the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THE REFERENCE CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cost-effectiveness analysis should ideally present a reference case in which the analysis is performed using a standard set of methods and assumptions for the measurement and reporting of costs and health effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/9\">",
"     9",
"    </a>",
"    ]. The reference case methodologies include the following considerations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Components belonging in the numerator or denominator of a cost-effectiveness ratio",
"     </li>",
"     <li>",
"      Measuring terms in the numerator of a cost-effectiveness ratio (costs)",
"     </li>",
"     <li>",
"      Valuing the health consequences in the denominator of a cost-effectiveness ratio",
"     </li>",
"     <li>",
"      Estimating effectiveness of interventions",
"     </li>",
"     <li>",
"      Time preferences and discounting",
"     </li>",
"     <li>",
"      Handling uncertainty in cost-effectiveness analysis",
"     </li>",
"     <li>",
"      Reporting guidelines\" [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/10\">",
"       10",
"      </a>",
"      ] with 38 specific items in a checklist for reporting the reference case cost-effectiveness analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reference case improves the comparability of cost-effectiveness analyses, thereby permitting the health policy makers to choose the most efficient use of public health resources in their funding decisions (",
"    <a class=\"graphic graphic_table graphicRef69531 \" href=\"UTD.htm?11/4/11341\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A consensus statement has been issued with regard to the details of how the reference case should be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Unfortunately, many cost-effectiveness analyses continue to be published that do not contain a reference case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TIME HORIZON AND DISCOUNT RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time horizon of an analysis reflects the length of time over which health benefits and costs should be considered and included in the analysis. Because of annual budgets and competing market forces, health payers usually consider short-term, one-year time horizons, but the societal perspective recommended in the reference case typically applies a long-term or lifetime time horizon. In such cases, time preferences for expenditures become important and are captured as the \"discount\" rate.",
"   </p>",
"   <p>",
"    Money available or spent now is more valuable than money available or spent in the future because of opportunity costs. As an example, one would prefer to receive money now as opposed to receiving the same amount a year from now because money available now can be put to immediate use. The discount rate quantifies this time preference and places all economic costs in terms of present value of money. The reference case recommends applying a 3 percent annual discount rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/9\">",
"     9",
"    </a>",
"    ], so spending $100 now equals spending $97 one year from now or spending $74 10 years from now. Because costs are discounted, the benefits of health interventions must also be discounted.",
"   </p>",
"   <p>",
"    Note that the discount rate is not an adjustment for inflation, which is a separate consideration. Even in the absence of inflation, most individuals would prefer to have an equivalent health benefit or money now as opposed to in the future. The discount rate captures this time preference. When data regarding costs are derived from different years, older costs are usually inflated to their equivalent values in more recent years so that there can be a consistent economic basis. If future medical inflation costs rise uniformly, then future purchasing power for health care remains the same, and there is no need to adjust for medical inflation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SENSITIVITY ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As underscored in the previous discussions, considerable uncertainty may remain regarding the parameters used to measure costs and health effects, even in the most carefully conducted cost-effectiveness studies. To help identify the most influential or important parameters and to assess the degree to which uncertainty in the parameter could affect the overall results, cost-effectiveness analyses usually perform multiple evaluations in which one or more of the parameters are varied across reasonable ranges. The ranges reflect intrinsic variability or regional variation. As an example, the cost of colonoscopy may be cheaper in some institutions or health care delivery settings compared with others; thus, to determine the cost-effectiveness of screening colonoscopy, the cost of a colonoscopy is varied over a range to determine the maximal cost at which it remains cost-effective. This process (termed \"sensitivity analysis\") allows for a reasonable appraisal about the parameters that are most important in the analysis, and the stability of the reference case results.",
"   </p>",
"   <p>",
"    Cost-effectiveness analyses that include a decision analysis routinely perform sensitivity analysis. Decision analysis involves the mathematical modeling of health outcomes, utilities (preference based estimates of the quality of life with various health conditions), and costs based on published estimates of key parameters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22471?source=see_link\">",
"     \"Decision analysis\"",
"    </a>",
"    .) The degree to which sensitivity analysis is performed (and thereby the rigor with which assumptions are tested) varies across decision analyses. Furthermore, economic data from clinical trials, as opposed to decision analyses, may omit sensitivity analysis or subgroup analyses.",
"   </p>",
"   <p>",
"    Sensitivity analyses have typically assessed the effect varying selected parameters related to cost-effectiveness one at a time. A more contemporary approach called Monte Carlo simulation permits all parameters to be varied simultaneously. These sophisticated analyses yield a cost-effectiveness acceptability curve, which account for uncertainty in all model estimates. The end result is that the curve displays the likelihood that a new intervention will have a cost-effectiveness ratio that falls below a particular societal &ldquo;willingness to pay.&rdquo; (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Interpretation'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Monte Carlo models can also be used to determine whether additional information about parameters used in the model (such as could be obtained by conducting additional research) would be useful. This can be highly valuable to policy makers who are required to decide whether the new therapy should be approved and paid for or whether public funds should instead be dedicated to further study the area to reduce uncertainty and clarify cost-effectiveness. As an example, the initial clinical trials for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    for Alzheimer&rsquo;s disease had follow-up shorter than 24 months while longer treatment would be expected to be required. Monte Carlo models suggested that research to determine its efficacy beyond 24 months had a potential economic value of $270 million [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS RATIO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average cost-effectiveness ratio divides each intervention's costs by its effectiveness. This can result in misleading conclusions about an intervention's cost-effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/3\">",
"     3",
"    </a>",
"    ]. A preferable way to express cost-effectiveness is \"incremental\" cost-effectiveness, which refers to the additional cost and the additional benefit of one intervention compared with another.",
"   </p>",
"   <p>",
"    Consider, for example, whether four or three stool guaiac tests should be performed annually for colon cancer screening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/19\">",
"     19",
"    </a>",
"    ]. Performing three annual guaiacs represents the standard of care against which performing four guaiacs is being compared. When applied to 10,000 people, three annual guaiacs results in a net cost of $130,999 and detects 71.9003 cases of colon cancer, and four annual guaiacs costs $148,116 and detects 71.9385 cases. The average cost-effectiveness of performing three or four tests annually is $1,810 or $2,059 per cancer detected; either appears to be reasonable.",
"   </p>",
"   <p>",
"    In contrast, the incremental cost-effectiveness ratio asks how much additional benefit and at what additional cost does performing four instead of three guaiacs provide. Dividing the net costs of four guaiacs minus the net costs of three guaiacs (incremental cost of four versus three guaiacs = $17,917) by the effectiveness of four guaiacs minus the effectiveness of three guaiacs (incremental benefit of four versus three guaiacs = 0.0382 additional cancers detected) yields an incremental cost-effectiveness ratio of $469,534 per additional cancer detected (an incremental cost 20 times higher than the average cost-effectiveness). The units are typically in dollars (or other units of currency) per effectiveness gained.",
"   </p>",
"   <p>",
"    Cost-utility analyses report results using a standard expression of cost-effectiveness, ie, the cost to increase life expectancy by one QALY (adjusted to one year of perfect health and discounted to its present value). The rationale for choosing this expression can be understood by the difficulty that can arise when trying to compare studies in which cost-effectiveness is expressed using different effectiveness metrics. As an example, the relative cost-effectiveness of a colon cancer detected versus a myocardial infarction prevented would leave a policy analyst in a quandary as to which was more valuable.",
"   </p>",
"   <p>",
"    The Multicenter Automatic Defibrillator Implantation Trial (MADIT) illustrates the calculation of the incremental cost-effectiveness ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/20\">",
"     20",
"    </a>",
"    ]. This randomized controlled study of asymptomatic patients at high risk for sudden cardiac death demonstrated that implantable cardiac defibrillators (ICD) can prevent sudden cardiac death compared with pharmacologic therapy. After 27 months, ICD-treated patients had significant reductions in the incidence of all-cause mortality, cardiac mortality, and arrhythmic deaths. Over a four-year period, the ICD group had an average survival of 3.46 years at a cost of $97,560 compared with survival of 2.66 years at a cost of $75,980 for the conventionally treated patients. Dividing the incremental cost of $21,580 by the incremental benefit of 0.8 years yields an incremental cost-effectiveness ratio of $27,000 per life-year saved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incremental cost-effectiveness ratio helps decision-makers determine whether or how a new intervention should be used. Lower ratios imply better cost-effectiveness. Using low osmolar contrast media for high-risk patients has an incremental cost-effectiveness of $22,600 per quality-adjusted life year gained, but if given to low-risk patient, its cost-effectiveness rises to $220,000 per quality-adjusted life year gained. With a limited budget of $1 million, spending it on low osmolar contrast for low-risk patients would add only 4.5 years while spending it on high-risk patients would add 44 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in the presence of uncertainty, the cost-effectiveness ratio can still be helpful in choosing among options. As an example, routine endoscopic screening has been recommended in Barrett's esophagus, a premalignant condition of the esophagus. The frequency with which endoscopic screening should be performed depends critically on the cancer risk in patients with the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/21\">",
"     21",
"    </a>",
"    ]. Although the actual risk is not known precisely, sensitivity analysis varying this key factor can help in choosing among different surveillance intervals (",
"    <a class=\"graphic graphic_figure graphicRef76263 \" href=\"UTD.htm?28/16/28941\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, the cost-effectiveness ratio can be helpful to determine the range of acceptable costs for new intervention or diagnostic test compared with an existing standard. In one study, for example, a stool DNA test for screening for colorectal cancer would be cost-effective compared with standard screening approaches if the test cost fell to $40 to $60 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the cost of stool DNA testing in 2010 was $350. The test would be more costly and less effective than other alternatives.",
"   </p>",
"   <p>",
"    While the incremental cost-effectiveness ratio is helpful, the context and absolute costs of different interventions also need to be incorporated into decision-making because the consistent selection of strategies based only upon cost may lead to a minimalist approach to providing services. Consider, for example, a disease that is invariably fatal within one week if left untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/8\">",
"     8",
"    </a>",
"    ]. Two treatment options are available. The first option costs $100 and produces a life expectancy of one year. The second option costs 10 times as much ($1000) but yields a life expectancy of five years. A practice based on cost-minimization would select the first option, yet the incremental cost-effectiveness of the second option is only $225 per year of life gained ($1000 -$100)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    (5 - 1). Although the first option has the lowest cost, it would be unacceptable when considering the severity of the illness, the degree of benefit, and the relatively low absolute cost of the second option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Having determined the incremental cost-effectiveness ratio, how should those ratios be interpreted? The examples presented above bring into focus two general methods for evaluating cost-effectiveness ratios.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first method is based upon the notion of \"willingness-to-pay.\" A decision-maker (such as an insurance company) may decide that it is only willing to pay a certain amount per unit of gain (such as QALYs) across all the services that it covers. Thus, the selection among options with different cost-effectiveness ratios would be based upon staying within this limit. In the example above, with a willingness to pay for all interventions that falls below $50,000 per quality-adjusted life year gained, the health care payer should fund low osmolar contrast for high-risk patients but not for low-risk patients.",
"     </li>",
"     <li>",
"      The second method involves comparing the cost-effectiveness ratio of an intervention with other well-accepted medical practices by examining a league table. A league table is a compilation of cost-effectiveness ratios for various treatments and diseases complying with the reference case (",
"      <a class=\"graphic graphic_table graphicRef69531 \" href=\"UTD.htm?11/4/11341\">",
"       table 1",
"      </a>",
"      ). As a general rule, interventions that yield a cost-effectiveness ratio of less than $50,000 to $100,000 per QALY gained have been considered to be acceptable in the United States and several other countries. This cutoff is also consistent with World Health Organization recommendations, which suggest that interventions with cost-effectiveness ratios less than 3 times the GDP per capita are &ldquo;cost-effective&rdquo; and those less than the GDP (about $46,000 for the US in 2010) are &ldquo;very cost-effective.&rdquo; The historical standard used for setting this threshold has been hemodialysis for chronic renal failure, which has an incremental cost-effectiveness ratio of $60,000 to $128,000 per quality-adjusted life year gained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, because of moral imperatives related to social justice (including that patients with rare or life-threatening diseases should still have access to effective therapies despite their expense), some medical interventions with high incremental cost-effectiveness ratios are still widely performed (eg, cardiac transplantation at a cost of $160,000 per life-year gained). On the other hand, these high incremental cost-effectiveness ratio interventions can drive health care costs up, potentially depriving others of access to basic health care.",
"   </p>",
"   <p>",
"    Despite the efforts to standardize analyses using the reference case, direct comparison of different cost-effectiveness studies may not be straightforward because studies were performed at different times, often using different methodologies and assumptions, and variable expressions of effectiveness. Furthermore, only rarely are there health conditions for which all the relevant treatment options have been compared rigorously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATING A COST-EFFECTIVENESS STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discussion presented above emphasizes that cost-effectiveness analysis is complex and that studies making claims regarding cost-effectiveness should receive the same level of scrutiny as other types of studies. The following questions can provide guidance when evaluating a cost-effectiveness analysis, although many additional features reflecting the conduct of the study and its quality can be considered in specific settings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26087/abstract/5,6,11,23-27\">",
"     5,6,11,23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Did the study compare well-defined strategies that are consistent with medical practice?",
"     </li>",
"     <li>",
"      Were the included patients representative of the types of patients that the analysis is intended to apply to?",
"     </li>",
"     <li>",
"      Were costs defined reasonably?",
"     </li>",
"     <li>",
"      Were all the relevant costs considered?",
"     </li>",
"     <li>",
"      Did the estimates of cost reflect those in the community in which the results are intended to apply?",
"     </li>",
"     <li>",
"      Were ranges of costs considered for key services?",
"     </li>",
"     <li>",
"      Was effectiveness expressed in relevant units such as QALYs gained? Was it reasonable to ignore quality of life if it was not considered?",
"     </li>",
"     <li>",
"      Was the time frame examined long enough for the expected benefits to have been observed?",
"     </li>",
"     <li>",
"      Were all the relevant outcomes considered?",
"     </li>",
"     <li>",
"      Was sensitivity analysis performed?",
"     </li>",
"     <li>",
"      Was the perspective defined clearly?",
"     </li>",
"     <li>",
"      Was a reference case presented?",
"     </li>",
"     <li>",
"      Were the findings discussed in context of other options available to treat the particular condition?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As economic pressures have increased, it is no longer sufficient for physicians to know simply about the safety, efficacy, and effectiveness of medical practices. Cost-effectiveness analysis provides a commonly-accepted method to evaluate the value or efficiency of new technologies and drugs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cost-effectiveness analysis or cost-utility analysis (a type of cost-effectiveness analysis) is most commonly used for performing economic analyses in healthcare. In these analyses, monetary and health outcomes are measured separately and the relative value of an intervention is measured as the additional cost to achieve an incremental health benefit such as dollars to prevent a case of cancer. In cost-utility analysis, the effectiveness metric becomes life expectancy adjusted for the morbidity or quality of life associated with the alternative strategies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Costs refer to the total net expenditures related to an intervention, including the costs of treatment, adverse treatment effects, and future possible savings from the prevention of disease or morbidity. They can be categorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Direct medical care (eg, physician time, test, or drug)",
"     </li>",
"     <li>",
"      Direct nonmedical care (eg, food, transportation, lodging, clothing, home aides, care by family members)",
"     </li>",
"     <li>",
"      Indirect morbidity and mortality (eg, lost productivity), and intangible (eg, pain and suffering)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Costs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effectiveness is typically measured in units that are relevant to the condition under study and are meaningful for the decision-maker. A standard outcome scale allows policy makers to compare the relative net health benefits of alternative funding decisions. Cost-utility analysis frequently uses quality-adjusted life years (QALYs) gained to reflect not only prolongation of life but also the quality of life associated with those years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To help identify the most influential or important parameters and to assess the degree to which uncertainty in the parameter could affect the overall results, cost-effectiveness analyses usually perform multiple evaluations in which one or more of the parameters are varied across reasonable ranges. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sensitivity analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions that yield a cost-effectiveness ratio of less than $50,000 to $100,000 per QALY gained have been considered to be acceptable in the United States and several other countries. The historical standard used for setting this threshold has been hemodialysis for chronic renal failure, which has an incremental cost-effectiveness ratio of $60,000 to $128,000 per quality-adjusted life year gained. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/1\">",
"      Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/2\">",
"      Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989; 262:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/3\">",
"      Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/4\">",
"      Provenzale D, Lipscomb J. Cost-effectiveness: definitions and use in the gastroenterology literature. Am J Gastroenterol 1996; 91:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/5\">",
"      Drummond MF, Richardson WS, O'Brien BJ, et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1997; 277:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/6\">",
"      O'Brien BJ, Heyland D, Richardson WS, et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1997; 277:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/7\">",
"      American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 2008; 148:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/8\">",
"      Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term \"cost effective\" in medicine. N Engl J Med 1986; 314:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/9\">",
"      Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/10\">",
"      Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/11\">",
"      Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/12\">",
"      Hlatky MA, Lipscomb J, Nelson C, et al. Resource use and cost of initial coronary revascularization. Coronary angioplasty versus coronary bypass surgery. Circulation 1990; 82:IV208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/13\">",
"      Froberg DG, Kane RL. Methodology for measuring health-state preferences--III: Population and context effects. J Clin Epidemiol 1989; 42:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/14\">",
"      Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988; 23:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/15\">",
"      Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982; 30:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/16\">",
"      Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978; 31:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/17\">",
"      Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/18\">",
"      Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002; 360:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/19\">",
"      Neuhauser D, Lweicki AM. What do we gain from the sixth stool guaiac? N Engl J Med 1975; 293:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/20\">",
"      Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 1998; 97:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/21\">",
"      Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/22\">",
"      Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010; 153:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/23\">",
"      Meltzer MI. Introduction to health economics for physicians. Lancet 2001; 358:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/24\">",
"      Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 2002; 106:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/25\">",
"      Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003; 41:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/26\">",
"      Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26087/abstract/27\">",
"      Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health 2003; 6:9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2780 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26087=[""].join("\n");
var outline_f25_30_26087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COSTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THE REFERENCE CASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TIME HORIZON AND DISCOUNT RATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SENSITIVITY ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COST-EFFECTIVENESS RATIO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATING A COST-EFFECTIVENESS STUDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2780|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/16/28941\" title=\"figure 1\">",
"      Optimal surveillance Barretts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/4/11341\" title=\"table 1\">",
"      Cost utility league table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22471?source=related_link\">",
"      Decision analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_30_26088="Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials";
var content_f25_30_26088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26088/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26088/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26088/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/30/26088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of therapies are beneficial in the management of patients with acute myocardial infarction (MI), including revascularization with either percutaneous coronary intervention or fibrinolysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, statins, and either angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence supporting the efficacy of ACE inhibitors and ARBs in this setting will be reviewed here. Recommendations for the use of ACE inhibitors and ARBs after MI, the use of ACE inhibitors in patients with heart failure (HF) due to systolic dysfunction, and the mechanisms by which ACE inhibitors might act are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACE INHIBITOR EFFECTS ON CARDIAC FUNCTION AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most randomized trials have demonstrated that ACE inhibitor therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    , or zofenopril started within 24 hours to 16 days following an acute MI improves the left ventricular ejection fraction (LVEF) at one month to one year [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/1-14\">",
"     1-14",
"    </a>",
"    ]. In these studies the great majority of patients had an ST elevation MI (STEMI); data are limited in patients with a non-ST elevation acute coronary syndrome (NSTEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition most patients were treated with either fibrinolytic therapy or no reperfusion; data in patients who underwent percutaneous coronary intervention (PCI) for MI are limited.",
"   </p>",
"   <p>",
"    The administration of an ACE inhibitor is also associated with an important improvement in patient survival. Large (50 lives saved per 1000 patients treated) mortality benefits post-MI have been demonstrated in patients with low LVEF, HF, or anterior MIs. Smaller benefits (five lives saved per 1000 treated) have been found in low-risk patients.",
"   </p>",
"   <p>",
"    The benefits derived from ACE inhibition in high-risk patients are generally greater than those achieved by other therapeutic interventions. As an example, a meta-analysis of the nine largest randomized prospective trials comparing intravenous fibrinolysis versus placebo demonstrated approximately 30 lives were saved per 1000 patients treated who presented within six hours of symptom onset. However, the effect of these other interventions are additive to those associated with ACE inhibition.",
"   </p>",
"   <p>",
"    The magnitude of the mortality benefit seen with ACE inhibitors given within 24 hours of chest pain onset is smaller in studies of all patients (with chest pain) than that seen in subsets of patients with MI (0.5 percent versus four to six percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effects in all patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the Fourth International Study of Infarct Survival (ISIS-4) and the GISSI-3 trial, which primarily consisted of patients with STEMI treated with fibrinolysis (approximately 70 percent in both studies), showed that the mortality benefit with an ACE inhibitor starts soon after therapy is began and persists for one year of follow-up (",
"    <a class=\"graphic graphic_figure graphicRef52159 \" href=\"UTD.htm?34/31/35326\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ISIS-4, 58,050 patients without persistent hypotension were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      (6.25 mg initial dose increased to 50 mg BID) or placebo within 24 hours after MI [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/14\">",
"       14",
"      </a>",
"      ]. The duration of therapy was one month. Captopril therapy was associated with a significant 7 percent proportional reduction in five week mortality, which persisted at 12 months; the absolute benefit at 12 months was 0.5 percent (12 versus 12.5 percent in the placebo group). The improvement was primarily limited to those with anterior MIs and was greater in patients with previous MI or HF.",
"     </li>",
"     <li>",
"      In GISSI-3, over 19,000 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      (5 mg initial dose followed by 10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo within the first 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/15\">",
"       15",
"      </a>",
"      ]. The duration of therapy was six weeks. The odds ratio for the combined outcome measure of mortality and severe ventricular dysfunction at six weeks was 0.90 (10 percent relative reduction) in the lisinopril group.",
"      <br/>",
"      <br/>",
"      Similar to the results in ISIS-4, the benefit from early treatment with lisinopril continued for up to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/16\">",
"       16",
"      </a>",
"      ] and as long as four years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/17\">",
"       17",
"      </a>",
"      ] despite discontinuation of the drug after six weeks. The mortality benefit with ACE inhibition was primarily seen in patients with diabetes, who comprised about 15 percent of the study population (13 versus 16 percent at six months) (",
"      <a class=\"graphic graphic_figure graphicRef63118 \" href=\"UTD.htm?8/25/8606\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Low ejection fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Survival and Ventricular Enlargement (SAVE) trial assigned 2231 patients with an LVEF of 40 percent or less to placebo or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    (titrated up to 50 mg TID) within 3 to 16 days following an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/5\">",
"     5",
"    </a>",
"    ]. None of the patients had overt HF on entry.",
"   </p>",
"   <p>",
"    After an average of 42 months follow-up,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    therapy was associated with a 19 percent (95% CI 3 to 32 percent) decrease in mortality (20 versus 25 percent for placebo), (",
"    <a class=\"graphic graphic_figure graphicRef66197 \" href=\"UTD.htm?21/60/22477\">",
"     figure 3",
"    </a>",
"    ), a 37 percent reduction (95% CI 20 to 50 percent) in the incidence of severe HF, a 22 percent reduction (95% CI 4-37) in hospitalization for HF, and a 25 percent (95% CI 5-40 percent) reduction in the incidence of recurrent MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/5,19\">",
"     5,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings on mortality and sudden death were noted in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     Trandolapril",
"    </a>",
"    Cardiac Evaluation (TRACE) trial in which trandolapril (titrated to a dose of 4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo was given to 1749 patients three to seven days after an acute MI that was associated with an LVEF &le;35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/7\">",
"     7",
"    </a>",
"    ]. At two to four year follow-up, there were 25 to 30 percent reductions in mortality (34.7 versus 42.3 percent with placebo), sudden death, and progression to severe HF in the patients treated with trandolapril. At a minimum follow-up of six years, patients receiving trandolapril had a life expectancy of 6.2 years versus 4.6 years for placebo (",
"    <a class=\"graphic graphic_figure graphicRef81385 \" href=\"UTD.htm?26/24/27022\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/20\">",
"     20",
"    </a>",
"    ]. The benefits persisted at 10 to 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast to the SAVE trial, no reduction in subsequent MI was seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of ACE inhibition in patients who develop HF post-MI was evaluated in the Acute Infarction",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     Ramipril",
"    </a>",
"    Efficacy trial (AIRE) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/8\">",
"     8",
"    </a>",
"    ]. This study randomly assigned 2006 patients with clinical evidence of HF to ramipril or placebo between day 3 and 10 post-MI. After an average of 15 months follow-up, ramipril was associated with a six percent absolute decrease in mortality (17 percent versus 23 percent with placebo). Ramipril had no effect upon the rate of reinfarction or stroke but significantly reduced the risk of sudden death by 30 percent, largely due to a reduction in progressive HF, which occurred in 45 percent of those who died suddenly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival benefit associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    was maintained long-term. Among 603 patients who were followed for a mean of 59 months, the mortality was significantly lower in those who received ramipril (28 versus 39 percent), representing a relative risk reduction of 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Early in anterior wall MI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     After no reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Trial randomly assigned 1556 patients with an anterior wall MI (two-thirds STEMI) who did not receive reperfusion therapy to zofenopril within 24 hours of chest pain onset (7.5 mg initial dose and progressively doubled every 12 hours until the target dose of 30 mg BID was reached) or placebo for six weeks. Zofenopril significantly lowered the primary end point of mortality plus severe HF at six weeks (7.1 versus 10.6 percent) and at one year (10 versus 14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     After fibrinolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of early ACE inhibition in patients with an anterior wall MI who are treated with a fibrinolytic agent has been assessed in several trials. Some studies showed improved outcomes with ACE inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/23\">",
"     23",
"    </a>",
"    ] while others did not [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/11,24\">",
"     11,24",
"    </a>",
"    ]. The inconsistent effects of early treatment with an ACE inhibitor in patients receiving fibrinolytic may have been due in part to the small number of patients in these studies. In a meta-analysis of three trials that included 845 patients who underwent fibrinolytic therapy, there was no evidence of benefit (attenuation of ventricular volumes) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     TIming of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several meta-analyses of ACE inhibitor trials have confirmed beneficial effects on mortality after an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. The most complete analysis examined early and late administration of an ACE inhibitor separately, and confirmed that both are associated with a mortality benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 11 trials of early administration (within 48 hours of infarction), ACE inhibitor therapy was associated with a significant reduction in mortality at one month (9.5 versus 10.1 percent).",
"     </li>",
"     <li>",
"      In four small trials of late administration (more than 48 hours after infarction), ACE inhibitor therapy was associated with a significant reduction in mortality at one year (14.3 versus 16.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another meta-analysis of three trials (SAVE, AIRE, and TRACE), all of which were included in the late administration group described above, documented both a long term mortality benefit and additional improvements in outcome with ACE inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction in mortality at three years (23.4 versus 29 percent for control, odds ratio 0.74) (",
"      <a class=\"graphic graphic_figure graphicRef58405 \" href=\"UTD.htm?28/62/29677\">",
"       figure 5",
"      </a>",
"      ). The absolute event-rate difference was 5.7 percent; to avoid one death 15 patients would have to be treated for 30 months. The benefits of treatment were apparent soon after the initiation of therapy, as a reduction in mortality was noted by six weeks after randomization (6 versus 7.9 percent).",
"     </li>",
"     <li>",
"      A significant reduction in the incidence of readmission for HF (12 versus 15.5 percent, odds ratio 0.73).",
"     </li>",
"     <li>",
"      A significant reduction in the incidence of reinfarction (10.8 versus 13.2 percent, odds ratio 0.80).",
"     </li>",
"     <li>",
"      No difference in the risk of stroke (4 versus 3.7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Class differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known whether all ACE inhibitors have an equivalent effect on survival after MI. This issue was addressed in a retrospective cohort study of 7512 patients who had an acute MI, filled a prescription for an ACE inhibitor within 30 days of discharge, and continued to receive the same drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/30\">",
"     30",
"    </a>",
"    ]. At one year, mortality was lower for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24152?source=see_link\">",
"     ramipril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"     fosinopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/29/24024?source=see_link\">",
"     quinapril",
"    </a>",
"    . However, this conclusion is limited by baseline differences in the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best documented mechanism by which these agents act is to reduce ventricular remodeling over days to weeks after myocardial damage. However, the very early mortality benefit may also be mediated by other, possibly neurohumoral mechanisms. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACE INHIBITOR EFFECTS ON ARRHYTHMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there is no evidence that ACE inhibitors have direct antiarrhythmic effects, blockade of the renin-angiotensin system, reduction in ventricular and atrial wall stress, interference with ion currents, and the decrease in sympathetic tone resulting from improved left ventricular function may reduce the development of atrial and ventricular arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a substudy of ISIS-4 involving 304 patients, ventricular ectopic beats per hour were significantly less frequent in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    compared to those on placebo at days 3 and 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/32\">",
"     32",
"    </a>",
"    ]. However, captopril therapy did not affect the frequency of complex ventricular arrhythmia or episodes of ventricular tachycardia.",
"   </p>",
"   <p>",
"    In the VHeFT II that randomly assigned 806 men with heart failure (HF) to",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"      hydralazine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"      isosorbide dinitrate",
"     </a>",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , the mortality rate was significantly lower in the enalapril group (16 versus 25 percent) after two years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/33\">",
"     33",
"    </a>",
"    ]. This benefit was attributable to a reduction in the incidence of sudden death and was more prominent in patients with less severe symptoms (NYHA class I or II).",
"   </p>",
"   <p>",
"    In a study of 58 patients with left ventricular dysfunction after MI randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    or placebo, patients who received captopril had a significant decrease in ventricular arrhythmia during a six month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/34\">",
"     34",
"    </a>",
"    ]. The left ventricular end systolic and end diastolic volumes at baseline and at six months were significantly increased in those with ventricular arrhythmia; an increase in left ventricular end diastolic volume, seen only in the placebo group, was an independent predictor of ventricular arrhythmia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=see_link\">",
"     \"Cardiac remodeling: Clinical assessment and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Effect on sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decreased risk of sudden death has been seen in some [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/7,22,35\">",
"     7,22,35",
"    </a>",
"    ] but not all trials [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 15,104 patients who were within 14 days of an acute MI found that ACE inhibitor therapy significantly reduced the risk of overall and cardiovascular mortality (odds ratio 0.82) and sudden death (odds ratio 0.80, absolute benefit about 1.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several mechanisms that might contribute to the reduction in sudden death including a reduction in sympathetic activity, improvement in substrate resulting from a reduction in ventricular remodeling and dilatation, and a decrease in recurrent MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations suggest that ACE inhibitors and ARBs may prevent the development of new or recurrent atrial fibrillation (AF) in a variety of clinical settings. Evidence that these agents reduce the incidence of AF in patients who have had an MI comes from the TRACE and SOLVD trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=see_link\">",
"     \"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ANGIOTENSIN II RECEPTOR BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin II receptor blockers (ARBs) act by a different mechanism than the ACE inhibitors, although both reduce the stimulation of angiotensin II receptors (",
"    <a class=\"graphic graphic_figure graphicRef55726 \" href=\"UTD.htm?9/23/9597\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19685?source=see_link\">",
"     \"Differences between angiotensin converting enzyme inhibitors and receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Comparison to ACE inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major trials have compared an ARB to an ACE inhibitor in patients with an acute MI: OPTIMAAL and VALIANT. The OPTIMAAL trial compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    (50 mg three times daily) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    (50 mg once daily) in 5770 high-risk patients after an acute ST elevation anterior infarction or reinfarction or after any MI associated with heart failure (HF) during the acute phase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/36\">",
"     36",
"    </a>",
"    ]. The following findings were noted at a mean follow-up of 2.7 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       Captopril",
"      </a>",
"      was associated with an almost significant trend toward lower mortality at 2.7 years than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      (16.4 versus 18.2 percent, relative risk 0.88, 95% CI 0.78-1.01).",
"     </li>",
"     <li>",
"      There was a similar trend with sudden cardiac death or resuscitated cardiac arrest (7.4 versus 8.7 percent), but no apparent difference in fatal or nonfatal reinfarction or all-cause hospitalization.",
"     </li>",
"     <li>",
"      Significantly fewer patients discontinued",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      (17 versus 23 percent) due primarily to less cough, angioedema, rash, and taste disturbance. The last two side effects are unusual with ACE inhibitors other than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       captopril",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The VALIANT trial found no difference in efficacy between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    in patients with HF occurring within 10 days after an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/37\">",
"     37",
"    </a>",
"    ]. This study included 14,808 patients with an acute MI (two-thirds with an STEMI) within the prior 10 days complicated by clinical or radiologic signs of HF, evidence of left ventricular systolic dysfunction, or both. Patients were randomly assigned to valsartan (target dose 160 mg twice daily), captopril (target dose 50 mg three times daily), or both agents (target regimen 80 mg valsartan twice daily and 50 mg captopril three times daily).",
"   </p>",
"   <p>",
"    At a median follow-up of 25 months, there was no difference among the three groups (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , or both) in the primary end point of all cause mortality (19.9, 19.5, and 19.3 percent respectively) or in the incidence of cardiovascular death, recurrent MI, or hospitalization for HF (31.1, 31.1, and 31.9 percent respectively). A noninferiority test confirmed that valsartan and captopril had equivalent efficacy.",
"   </p>",
"   <p>",
"    ARBs likely reduce the incidence of myocardial infarction to the same degree as ACE-inhibitors; in VALIANT, the rate of reinfarction was similar in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/38\">",
"     38",
"    </a>",
"    ]. The magnitude of this benefit can be estimated using a meta-analysis which found that ACE inhibitors significantly reduced the incidence of reinfarction compared to placebo (10.8 versus 13.2 percent, odds ratio 0.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, neither OPTIMAAL nor VALIANT found ARBs to be superior to ACE inhibitors in patients with an acute MI. Based upon VALIANT,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    at a dose of 160 mg twice daily appears to be as effective as an ACE inhibitor for reduction in mortality after an MI. It is possible that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    at a higher dose than that used in OPTIMAAL (eg, 100 mg once daily) would be similarly effective, although this has not been proven directly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Combination with ACE inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned in the preceding section, the VALIANT trial did not find a benefit of combined therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    compared to monotherapy with either drug alone in patients with HF occurring within 10 days after an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26088/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse events leading to a reduction in drug dose occurred more frequently with combination therapy than with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    alone (34.8 versus 29.4 and 28.4 percent). Hypotension and renal dysfunction occurred more often in the valsartan arm, while cough, rash, and taste disturbance occurred more often in the captopril arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of individual therapies are beneficial in the management of patients with acute myocardial infarction (MI), including revascularization with percutaneous coronary intervention or fibrinolysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, and statins. Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) have beneficial effects on mortality after an acute MI. Neither class of drugs has been shown to be superior to the other. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'ACE inhibitor effects on cardiac function and mortality'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The evidence supporting the efficacy of ACE inhibitors and ARBs in this setting is reviewed in this topic. Recommendations for the use of ACE inhibitors and ARBs after MI, the use of ACE inhibitors in patients with heart failure (HF) due to systolic dysfunction, and the mechanisms by which ACE inhibitors might act are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence of benefit of combined therapy with both classes of drugs compared to monotherapy with either drug alone in patients with HF occurring within 10 days after an acute MI. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Combination with ACE inhibitor'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/1\">",
"      Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988; 319:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/2\">",
"      Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991; 337:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/3\">",
"      St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/4\">",
"      Schulman SP, Weiss JL, Becker LC, et al. Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarction. Am J Cardiol 1995; 76:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/5\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/6\">",
"      Wright RA, Flapan AD, Alberti KG, et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/7\">",
"      K&oslash;ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/8\">",
"      Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/9\">",
"      Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/10\">",
"      Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/11\">",
"      van Gilst WH, Kingma JH, Peels KH, et al. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). J Am Coll Cardiol 1996; 28:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/12\">",
"      Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/13\">",
"      Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/14\">",
"      ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/15\">",
"      GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/16\">",
"      Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. J Am Coll Cardiol 1996; 27:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/17\">",
"      Ferguson JJ. Meeting highlights. Highlights of the 20th congress of the European society of cardiology. Circulation 1999; 99:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/18\">",
"      Zuanetti G, Latini R, Maggioni AP, et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/19\">",
"      Rutherford JD, Pfeffer MA, Moy&eacute; LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994; 90:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/20\">",
"      Torp-Pedersen C, K&oslash;ber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/21\">",
"      Buch P, Rasmussen S, Abildstrom SZ, et al. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J 2005; 26:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/22\">",
"      Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/23\">",
"      Borghi C, Marino P, Zardini P, et al. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J 1998; 136:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/24\">",
"      Baur LH, Schipperheyn JJ, van der Wall EE, et al. Beneficial effect of enalapril on left ventricular remodelling in patients with a severe residual stenosis after acute anterior wall infarction. Eur Heart J 1997; 18:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/25\">",
"      de Kam PJ, Voors AA, van den Berg MP, et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. J Am Coll Cardiol 2000; 36:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/26\">",
"      Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003; 115:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/27\">",
"      Flather MD, Yusuf S, K&oslash;ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/28\">",
"      Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/29\">",
"      Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/30\">",
"      Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/31\">",
"      Hennessy S, Kimmel SE. Is improved survival a class effect of angiotensin-converting enzyme inhibitors? Ann Intern Med 2004; 141:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/32\">",
"      Budaj A, Cybulski J, Cedro K, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction. Randomized, placebo-controlled substudy of ISIS-4. Eur Heart J 1996; 17:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/33\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/34\">",
"      S&oslash;gaard P, G&oslash;tzsche CO, Ravkilde J, et al. Ventricular arrhythmias in the acute and chronic phases after acute myocardial infarction. Effect of intervention with captopril. Circulation 1994; 90:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/35\">",
"      Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/36\">",
"      Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/37\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/38\">",
"      McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26088/abstract/39\">",
"      Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose. N Engl J Med 2003; 349:1963.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 71 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26088=[""].join("\n");
var outline_f25_30_26088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACE INHIBITOR EFFECTS ON CARDIAC FUNCTION AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effects in all patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Low ejection fraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Early in anterior wall MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - After no reperfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - After fibrinolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TIming of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Class differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACE INHIBITOR EFFECTS ON ARRHYTHMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ventricular arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Effect on sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ANGIOTENSIN II RECEPTOR BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Comparison to ACE inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Combination with ACE inhibitor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/71\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/71|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/31/35326\" title=\"figure 1\">",
"      Benefit of ACE inhibitors in acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/25/8606\" title=\"figure 2\">",
"      Lisinopril reduces mortality in patients with diabetes after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/60/22477\" title=\"figure 3\">",
"      Captopril lowers cardiovascular mortality post-MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/24/27022\" title=\"figure 4\">",
"      Trandolapril lowers mortality after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/62/29677\" title=\"figure 5\">",
"      ACE inhibitors improve outcome after MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/23/9597\" title=\"figure 6\">",
"      Comparison of the actions of ACE inhibitors and ARBs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20503?source=related_link\">",
"      ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1799?source=related_link\">",
"      Angiotensin converting enzyme inhibitors in acute myocardial infarction: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/842?source=related_link\">",
"      Cardiac remodeling: Clinical assessment and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19685?source=related_link\">",
"      Differences between angiotensin converting enzyme inhibitors and receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_30_26089="Diagnosis of Parkinson disease";
var content_f25_30_26089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26089/contributors\">",
"     Kelvin L Chou, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26089/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26089/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/30/26089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by any combination of four cardinal signs: rest tremor, rigidity, bradykinesia, and gait disturbance. An accurate diagnosis of PD rests on the clinician's ability to recognize its characteristic signs and associated symptoms, especially in the early stages. Correct diagnosis is fundamental to the appropriate therapy of PD, even though the same menu of antiparkinson drugs is used to treat all of the various parkinsonian syndromes.",
"   </p>",
"   <p>",
"    This topic will review the diagnosis of PD. Other aspects of PD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4277?source=see_link\">",
"     \"Nonpharmacologic management of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of parkinsonism (ie, tremor, bradykinesia, rigidity, and postural instability) can be prominent in neurodegenerative disorders other than idiopathic PD, including dementia with Lewy bodies, corticobasal degeneration, multiple system atrophy, and progressive supranuclear palsy (",
"    <a class=\"graphic graphic_table graphicRef58941 \" href=\"UTD.htm?13/1/13340\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Furthermore, parkinsonism is seen in a wide variety of other conditions (secondary parkinsonism) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Distinguishing PD from these parkinsonian syndromes can be difficult, particularly in the early stages of disease. Essential tremor may also be confused with Parkinson disease (PD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Essential tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Essential tremor (ET) is the most common neurologic cause of action tremor, with an estimated prevalence worldwide of up to 5 percent of the population. The incidence of ET increases with age, although it often affects young individuals, especially when it is familial. The neuropathologic basis for ET is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of tremor\", section on 'Essential tremor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Essential tremor is most often symmetric but can be unilateral, particularly early in the course of ET. It usually affects the hands and arms and can also involve the head, voice, chin, trunk, and legs. Tremor typically becomes immediately apparent in the arms when they are held outstretched or when they are engaged in activities such as writing or eating.",
"   </p>",
"   <p>",
"    Differentiating the action tremor of ET from the classic resting tremor of PD should be straightforward (",
"    <a class=\"graphic graphic_table graphicRef60694 \" href=\"UTD.htm?36/56/37771\">",
"     table 2",
"    </a>",
"    ). However, some patients with PD also have a postural-action tremor indistinguishable from ET. Likewise, patients with severe ET may have a rest component to their tremor. Furthermore, some patients with PD may have a re-emergent tremor: a postural tremor that manifests after a latency of several seconds with a frequency typical of the rest tremor in PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This distinction is important, as patients with a re-emergent rest tremor may be misdiagnosed as having essential tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of subtle bradykinesia or micrographia in early cases of parkinsonian postural tremor may support the diagnosis of idiopathic PD, although these signs may not appear until later on. However, it is important to be aware that elderly patients with ET may have mild bradykinesia and limb rigidity as a nonspecific accompaniment of aging. Head tremor is more likely to be a manifestation of ET, whereas tremor of the jaw or lips is more typically parkinsonian. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of tremor\", section on 'Essential tremor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110046802\">",
"    <span class=\"h2\">",
"     SWEDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term SWEDD (Scans Without Evidence of Dopaminergic Deficit) has been used to designate patients with relatively isolated upper extremity resting and postural tremor resembling early PD who fail to evolve over time into more generalized PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/6\">",
"     6",
"    </a>",
"    ]. Unlike patients with PD, these individuals lack evidence for nigrostriatal dopamine deficiency on dopamine transporter imaging (see",
"    <a class=\"local\" href=\"#H18\">",
"     'DaTscan'",
"    </a>",
"    below). Patients with SWEDD sometimes exhibit reduced arm swing and mild focal dystonia on the affected side, and may have jaw or head tremor or facial hypomimia, but no signs of parkinsonian akinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/6\">",
"     6",
"    </a>",
"    ]. They are therefore to be distinguished from individuals with tremor-dominant PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dementia with Lewy bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dementia with Lewy bodies (DLB) is the second most common cause of neurodegenerative dementia after Alzheimer disease and is characterized clinically by visual hallucinations, fluctuating cognition, and parkinsonism. Other associated symptoms include repeated falls, syncope, autonomic dysfunction, neuroleptic sensitivity, delusions, hallucinations in nonvisual modalities, sleep disorders, and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 40 percent of patients with PD eventually develop dementia, and the differentiation of Parkinson disease dementia (PDD) from DLB is somewhat arbitrary. In PDD, dementia occurs in the setting of well established parkinsonism, while in DLB, dementia usually occurs concomitantly with or before the development of parkinsonian signs. Thus, patients are classified as having PDD if parkinsonism is present for more than one year before the onset of dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link\">",
"     \"Parkinson disease dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Corticobasal degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with corticobasal degeneration can have asymmetric parkinsonism including bradykinesia, rigidity, and postural instability. More distinctive features can include ideomotor apraxia, alien limb phenomenon, aphasia, and loss of cortical sensory function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/7\">",
"     7",
"    </a>",
"    ]. Absence of tremor and lack of levodopa response are typical for corticobasal degeneration and help to distinguish it from PD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5354?source=see_link\">",
"     \"Corticobasal degeneration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Multiple system atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndromes of olivopontocerebellar atrophy, striatonigral degeneration, and Shy-Drager are now collectively known as multiple system atrophy. Clinical aspects of multiple system atrophy are reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=see_link\">",
"     \"Multiple system atrophy: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6870?source=see_link\">",
"     \"Multiple system atrophy: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple system atrophy commonly presents with parkinsonism, but patients also have varying degrees of dysautonomia, cerebellar involvement, and pyramidal signs. The prominence of these manifestations along with symmetry of onset, absence of tremor, and poor response to levodopa suggest this diagnosis rather than PD. However, some cases of multiple system atrophy may demonstrate responsiveness to levodopa, including motor fluctuations and dyskinesia, early in the course of the disease, with declining benefit over time. Cognitive function in multiple system atrophy tends to be relatively well preserved compared with PD and other parkinsonian syndromes, probably reflecting a lesser degree of cortical involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Progressive supranuclear palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive supranuclear palsy (PSP), also known as Steele Richardson Olszewski syndrome, is an uncommon but not rare parkinsonian syndrome that can mimic PD in its early phase. Characteristic features of PSP include a vertical supranuclear palsy with downward gaze abnormalities and postural instability with unexplained falls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Bradykinesia and rigidity are typically symmetrical in onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/10\">",
"     10",
"    </a>",
"    ]. Apathy, disinhibition, dysphoria, and anxiety are common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/11\">",
"     11",
"    </a>",
"    ]. The typical rest tremor of PD is rare in PSP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26090?source=see_link\">",
"     \"Progressive supranuclear palsy (PSP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pseudobulbar palsy with associated dysarthria and dysphagia develops in approximately 80 percent or more of patients with PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/12\">",
"     12",
"    </a>",
"    ]. A frontal lobe-like dementia syndrome occurs in a similar percentage, although the cognitive impairment may be mild in the first few years after clinical disease onset. The overall course is relentlessly progressive, with death occurring at a median of six years after onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to levodopa in PSP is typically poor, but about 20 percent of patients have some improvement initially or in the early stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105734326\">",
"    <span class=\"h2\">",
"     Idiopathic basal ganglia calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic basal ganglia calcification (IBGC), also known as bilateral striatopallidodentate calcinosis, Fahr syndrome, or Fahr disease, is a rare neurodegenerative condition characterized by the accumulation of calcium deposits in the basal ganglia and other brain regions, most easily visualized on CT scan, and a variable phenotype that can include one or more features of parkinsonism, chorea, dystonia, cognitive impairment, or ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/14\">",
"     14",
"    </a>",
"    ]. Onset of symptoms usually occurs between ages 20 to 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The familial form of IBGC is usually inherited in autosomal dominant fashion and is genetically heterogeneous [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/16\">",
"     16",
"    </a>",
"    ]. Familial IBGC has been linked to mutations in the SLC20A2 gene on chromosome 8p11.2 in a number of families [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, it has been linked to chromosome region 14q in one multi-generational family [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/18\">",
"     18",
"    </a>",
"    ] and to a locus on chromosome 2q37 in another [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sporadic and familial forms of IBGC are",
"    <strong>",
"     not",
"    </strong>",
"    associated with disorders of calcium or parathyroid hormone metabolism, such as hypoparathyroidism or pseudohypoparathyroidism. However, the localization of intracranial and basal ganglia calcification that can occur with hypoparathyroidism is similar to that seen in IBGC. By comparison, more limited basal ganglia calcification is a nonspecific neuroimaging finding seen in a number of infectious, metabolic, and genetic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/20\">",
"     20",
"    </a>",
"    ]. It is also an incidental finding in approximately 1 percent of head CT scans [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other neurodegenerative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkinsonism may develop in late stages of Alzheimer disease. However, the relative timing of the appearance of dementia and parkinsonism is usually obvious, such that the late onset of parkinsonism, in itself, does not lead to confusion about the diagnosis of Alzheimer disease.",
"   </p>",
"   <p>",
"    Parkinsonism may also occur in several other disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Huntington disease (rigid form) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=see_link\">",
"       \"Huntington disease: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Frontotemporal dementia with parkinsonism linked to chromosome 17 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"       \"Frontotemporal dementia: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spinocerebellar ataxias and dentatorubral pallidoluysian atrophy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=see_link\">",
"       \"The spinocerebellar ataxias\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Secondary parkinsonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of conditions can cause secondary parkinsonism, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs (eg, classic and atypical antipsychotic agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"       reserpine",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Toxins (eg, carbon disulfide, carbon monoxide, cyanide, MPTP, manganese, organic solvents).",
"     </li>",
"     <li>",
"      Head trauma, isolated or repeated (eg, boxing).",
"     </li>",
"     <li>",
"      Structural brain lesions that affect striatonigral circuits (eg, hydrocephalus, chronic subdural hematoma, tumor). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=see_link\">",
"       \"Normal pressure hydrocephalus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"       \"Clinical presentation and diagnosis of brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic and miscellaneous disorders (eg, Wilson's disease, hypoparathyroidism and pseudohypoparathyroidism, chronic liver failure, extrapontine myelinolysis, neurodegeneration with brain iron accumulation, neuroacanthocytosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"       \"Epidemiology and pathogenesis of Wilson disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"       \"Clinical manifestations of hypocalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"       \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link\">",
"       \"Spiculated cells (echinocytes and acanthocytes) and target cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections (eg, encephalitis lethargica or Economo's encephalitis,",
"      <span class=\"nowrap\">",
"       HIV/AIDS,",
"      </span>",
"      neurosyphilis, prion disease, progressive multifocal leukoencephalopathy, toxoplasmosis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=see_link\">",
"       \"Approach to HIV-infected patients with central nervous system lesions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"       \"Neurosyphilis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link\">",
"       \"Diseases of the central nervous system caused by prions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"       \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebrovascular disease. One theory holds that small vessel disease, particularly multiple lacunar infarcts in the basal ganglia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Binswanger disease, causes a \"vascular parkinsonism\". It should be noted that this entity is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1\">",
"       1",
"      </a>",
"      ], in part because most basal ganglia infarcts are not associated with parkinsonian signs [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Nevertheless, neuropathologic evidence suggests that mild parkinsonian signs in old age, particularly parkinsonian gait, are associated with the presence of macroscopic infarcts, microscopic infarcts, and arteriolosclerosis (ie, small vessel disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"       \"Lacunar infarcts\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generally, the clinical history, associated features, and laboratory or radiologic findings in these cases allow the clinician to distinguish secondary parkinsonism and its underlying cause from PD or other primary parkinsonian syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Drug-induced parkinsonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the conditions causing secondary parkinsonism, drug-induced parkinsonism is the most common, and antipsychotic and antiemetics drugs are the most frequent offenders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Movement disorders such as akathisia and orofacial dyskinesia may be associated with chronic neuroleptic use and, if present, can be useful for distinguishing drug-induced parkinsonism from PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, drug-induced parkinsonism can have clinical features identical to PD, including asymmetric onset with rest tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=see_link\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While drug-induced parkinsonism is usually reversible, persistent or progressive parkinsonism is seen in a minority of cases after drug withdrawal. It is unclear if this persistence is due to ongoing toxicity of the responsible drug or to the presence of an underlying parkinsonian syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practical diagnosis of PD during life is based on clinical impression. There are no physiologic tests or blood tests for confirming the diagnosis, and neurodiagnostic testing with computerized imaging is almost always unrevealing. The true \"gold standard\" for diagnosis is neuropathologic examination.",
"   </p>",
"   <p>",
"    It is generally accepted that bradykinesia, plus one of the other two cardinal manifestations (tremor, rigidity) must be present in order to make the diagnosis of idiopathic PD. In addition, an excellent response to dopaminergic therapy is an important criterion for the diagnosis. Other clinical features that are supportive of the diagnosis are unilateral onset, presence of a rest tremor, and a persistent asymmetry throughout the course of the disease with the side of onset most affected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Response to dopaminergic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, an excellent response to dopaminergic therapy is an important supportive feature for establishing the diagnosis of PD. The response to dopaminergic therapy in most parkinsonian syndromes is reduced or absent compared with the response in PD. However, up to 20 percent of patients with parkinsonism due to multiple system atrophy may respond initially to levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/31\">",
"     31",
"    </a>",
"    ], as may a substantial proportion of those with vascular parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An acute dopaminergic challenge test consists of rater-blinded assessment of parkinsonian symptoms using the Unified Parkinson Disease Rating Scale (UPDRS) before and after a dose of levodopa (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    <span class=\"nowrap\">",
"     25/250",
"    </span>",
"    mg) or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    (1.5 to 4.5 mg). Although there is no standard definition, a challenge is considered positive if there is a clinically significant improvement in the UPDRS score (usually in the range of 15 to 30 percent or more) one hour after levodopa administration or 20 minutes after apomorphine injection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and practice parameter from the American Academy of Neurology (AAN) published in 2006 concluded that levodopa and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    challenge tests should be considered when the diagnosis of PD is uncertain, as both tests are \"probably useful\" in distinguishing PD from other parkinsonian syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/35\">",
"     35",
"    </a>",
"    ]. An earlier systematic review found that both apomorphine and levodopa challenge tests had similar sensitivity and specificity for the diagnosis of idiopathic PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the exact role of acute levodopa or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/14/21734?source=see_link\">",
"     apomorphine",
"    </a>",
"    challenge for the diagnosis of PD in clinical practice remains unclear. The problem with challenge testing is illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to 30 percent of patients with PD may not respond to acute dopaminergic challenges",
"     </li>",
"     <li>",
"      Approximately 20 to 30 percent of patients with a positive acute dopaminergic challenge will go on to develop another parkinsonian syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In practice, when patients have mild symptoms that do not interfere with daily activities, it may not be advisable to institute dopaminergic therapy purely for diagnostic purposes. When PD symptoms begin to limit a patient's quality of life, a long-term trial of dopaminergic or levodopa therapy may be just as adequate as an acute dopaminergic challenge.",
"   </p>",
"   <p>",
"    The vast majority of patients with idiopathic PD will enjoy a significant therapeutic response to an adequate trial of moderate doses of levodopa (400 to 600 mg daily). Complete absence of response to a dose of 1000 to 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for at least two months strongly suggests that the original diagnosis of PD was incorrect and that the diagnosis should be revised to one of the other parkinsonian syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Features suggesting an alternative diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the 2006 AAN systematic review and practice parameter, a number of clinical features in early stages of disease are probably useful for distinguishing other forms of parkinsonism from PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Falls at presentation or early in the course of the disease",
"     </li>",
"     <li>",
"      Poor response to levodopa",
"     </li>",
"     <li>",
"      Symmetrical motor signs",
"     </li>",
"     <li>",
"      Rapid progression to Hoehn and Yahr stage 3 (",
"      <a class=\"graphic graphic_table graphicRef63585 \" href=\"UTD.htm?2/34/2603\">",
"       table 3",
"      </a>",
"      ) with mild to moderate disease and some postural instability, but physically independent",
"     </li>",
"     <li>",
"      Lack of tremor",
"     </li>",
"     <li>",
"      Dysautonomia, early in the disease course, as manifested by urinary",
"      <span class=\"nowrap\">",
"       urgency/incontinence",
"      </span>",
"      and fecal incontinence, urinary retention requiring catheterization, persistent erectile failure, or symptomatic orthostatic hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional historical or clinical features that may suggest a diagnosis other than PD (",
"    <a class=\"graphic graphic_table graphicRef58941 \" href=\"UTD.htm?13/1/13340\">",
"     table 1",
"    </a>",
"    ) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of encephalitis",
"     </li>",
"     <li>",
"      History of repeated head injury",
"     </li>",
"     <li>",
"      History of recurrent strokes and stepwise progression of parkinsonism",
"     </li>",
"     <li>",
"      Antipsychotic drug treatment at the onset of symptoms",
"     </li>",
"     <li>",
"      Presence of neoplasm or hydrocephalus on neuroimaging",
"     </li>",
"     <li>",
"      Cerebellar signs",
"     </li>",
"     <li>",
"      Supranuclear gaze palsy",
"     </li>",
"     <li>",
"      Dementia preceding or occurring concurrently with parkinsonism",
"     </li>",
"     <li>",
"      Babinski sign",
"     </li>",
"     <li>",
"      Presence of apraxia",
"     </li>",
"     <li>",
"      Strictly unilateral features after three years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105734443\">",
"    <span class=\"h2\">",
"     Diagnostic accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the clinical diagnosis of idiopathic PD may seem relatively simple, the accuracy of such a diagnosis can be as low as 75 percent when neuropathological examination is used as the diagnostic gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/30,37\">",
"     30,37",
"    </a>",
"    ]. On the other hand, diagnostic accuracy is increased to as high as 90 percent if patients are followed long-term by movement disorders specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An early diagnostic error rate of approximately 10 percent has been documented in some long-term studies of the natural history of PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/40\">",
"     40",
"    </a>",
"    ]. The most likely explanation is that other parkinsonian syndromes, such as progressive supranuclear palsy and multiple system atrophy, can mimic idiopathic PD early in the course of illness, before the later appearance of the signature symptoms, such as disordered eye movements seen with progressive supranuclear palsy or severe autonomic insufficiency that occurs with multiple system atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ancillary tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurodiagnostic testing is almost always unhelpful in the evaluation of suspected PD. The AAN systematic review and practice parameter published in 2006 found insufficient evidence to support or refute the value of certain ancillary tests for distinguishing PD from other parkinsonian syndromes, including magnetic resonance imaging (MRI), ultrasound of the brain parenchyma, 18F fluorodeoxyglucose (FDG) positron-emission tomography (PET), urodynamics, autonomic testing, and urethral or anal electromyography [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Conventional MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;While neuroimaging is usually nondiagnostic in the evaluation of suspected PD, magnetic resonance imaging (MRI) of the brain should be performed to exclude specific structural abnormalities (eg, hydrocephalus, tumor, or lacunar infarcts). Brain MRI may also be helpful in patients with clinical findings that suggest atypical parkinsonism.",
"   </p>",
"   <p>",
"    As examples, MRI may reveal thinning of the anteroposterior diameter of the midbrain with enlargement of the posterior third ventricle in moderate to advanced-stage progressive supranuclear palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], and MRI may show atrophy of the brainstem and cerebellum in multiple system atrophy, as well as putaminal hypointensity with a slit-like hyperintensity of the outer margin of the putamen on T2-weighted imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, the sensitivity of conventional MRI is suboptimal for distinguishing other parkinsonian syndromes from PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1,46\">",
"     1,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Newer MRI techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;More advanced MRI techniques, including MR volumetry, MR spectroscopy, magnetization transfer imaging, diffusion-weighted MRI, and diffusion tensor MRI, are promising methods that may offer higher sensitivity than conventional MRI for separating atypical parkinsonian syndromes from idiopathic PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. Further study is needed to establish the diagnostic utility of these methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     DaTscan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Striatal dopamine transporter imaging using 123I-FP-CIT single photon emission tomography (DaTscan) can reliably distinguish patients with PD and other parkinsonian syndromes (ie, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration) from controls or patients with essential tremor, but it cannot differentiate PD and the other parkinsonian syndromes from one another [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1,52,53\">",
"     1,52,53",
"    </a>",
"    ]. The available evidence suggests that the overall accuracy of DaTscan for parkinsonian syndromes is equal to but not better than the accuracy of a carefully obtained clinical diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/54\">",
"     54",
"    </a>",
"    ]. If one assumes that the detection of a striatal dopamine deficiency by DaTscan is the diagnostic gold standard for parkinsonian syndromes (a valid assumption since striatal dopamine deficiency always precedes the earliest symptoms of PD by several years), then the",
"    <strong>",
"     sensitivity",
"    </strong>",
"    of the clinical diagnosis is high in both early and advanced PD. However, the",
"    <strong>",
"     specificity",
"    </strong>",
"    varies with the duration of the illness; the clinical diagnosis in advanced PD has a high specificity, while the clinical diagnosis in early PD has a specificity of only 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the data [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] and our clinical experience, we suggest the use of DaTscan for the following scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients for whom the diagnosis is unclear after serial clinical evaluations, such as those with long standing essential tremor who later appear to have PD because of a change in the character of the tremor but fail to respond unequivocally to levodopa",
"     </li>",
"     <li>",
"      Patients who are possible candidates for deep brain stimulation but for whom the diagnosis of essential tremor versus PD versus some other cause (eg, dystonia) is unclear and where an accurate diagnosis determines the target of deep brain stimulation (eg, thalamic ventral intermediate nucleus versus subthalamic",
"      <span class=\"nowrap\">",
"       nucleus/globus",
"      </span>",
"      pallidus interna)",
"     </li>",
"     <li>",
"      To firmly establish a diagnosis of a parkinsonian syndrome in equivocal cases when recruiting for a clinical trial, particularly if the focus is neuroprotection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there is concern that with widespread use of DaTscan, technical problems in some centers might lead to an increased false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/54,56\">",
"     54,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84789572\">",
"    <span class=\"h3\">",
"     PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) shows decreased [18F]-fluorodopa tracer uptake in the caudate and putamen in patients with early PD compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. With [18F]-fluorodeoxyglucose (FDG) PET, which reveals regional cerebral glucose metabolism, patients with PD have a relative increase in metabolism of the pallidum, posterior putamen, and pons along with a relative decrease in metabolism of certain frontal and parieto-occipital regions.",
"   </p>",
"   <p>",
"    The results of several studies suggest that the diagnostic accuracy of FDG PET is greater than that of striatal dopamine transporter imaging for discriminating PD from atypical parkinsonian syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/59\">",
"     59",
"    </a>",
"    ], and that FDG PET has a good specificity for distinguishing the different atypical parkinsonian syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. However, the availability of PET is generally limited to research centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain parenchyma sonography (also called transcranial ultrasound) is being studied for its potential role in the preclinical diagnosis of PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Prospective studies in patients with early parkinsonism suggest that hyperechogenicity of the substantia nigra is predictive of the clinical diagnosis of PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/64\">",
"     64",
"    </a>",
"    ]. Hyperechogenicity of the substantia nigra has been reported in approximately 90 percent of patients with clinical PD compared with approximately 10 percent of patients with multiple system atrophy, progressive supranuclear palsy, or SWEDD (see",
"    <a class=\"local\" href=\"#H110046802\">",
"     'SWEDD'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. These data suggest that sonography could be a useful tool to distinguish between PD and other parkinsonian syndromes. However, further research is necessary to establish the utility and diagnostic accuracy of this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Olfactory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olfactory testing is another promising method for the early diagnosis of PD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/1,67\">",
"     1,67",
"    </a>",
"    ], as olfactory dysfunction is common in PD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations of Parkinson disease\", section on 'Olfactory dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, olfactory dysfunction is not associated with corticobasal degeneration, progressive supranuclear palsy, or essential tremor, and is mild or nonexistent in multiple system atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/68\">",
"     68",
"    </a>",
"    ]. Furthermore, it is not associated with vascular parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006 AAN systematic review and practice parameter concluded that olfactory testing should be considered and is probably useful for distinguishing corticobasal degeneration and progressive supranuclear palsy (normal olfaction) from PD (impaired olfaction), but not PD from multiple system atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/35\">",
"     35",
"    </a>",
"    ]. Olfactory testing is seldom used in clinical practice as a diagnostic test for PD, but test materials such as the University of Pennsylvania Smell Identification Test and Sniffin Sticks are commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Autonomic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of autonomic function, including urodynamic testing, urethral or anal sphincter EMG, sympathetic skin responses, Quantitative Sudomotor Axon Reflex Test, tilt table testing, and heart rate variability during forced respirations, has been examined as a potential tool for differentiating PD from other parkinsonian syndromes, especially multiple system atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26089/abstract/35\">",
"     35",
"    </a>",
"    ]. These tests, however, are generally not widely available, and there is insufficient evidence to recommend their routine use as diagnostic tests for PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"       \"Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate diagnosis of Parkinson disease (PD) rests on the clinician's ability to recognize its characteristic signs and associated symptoms (rest tremor, rigidity, akinesia, and gait disturbance), especially in the early stages.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of PD is extensive. Essential tremor may be confused with PD. Furthermore, parkinsonism can be a prominent feature of several neurodegenerative disorders in addition to idiopathic PD. The most common of these is dementia with Lewy bodies. Less common are the atypical parkinsonian syndromes, such as corticobasal degeneration, multiple system atrophy, and progressive supranuclear palsy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide variety of conditions can cause secondary parkinsonism. Of these, drug-induced parkinsonism is the most common, and antipsychotic and antiemetics drugs are the most frequent offenders. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Secondary parkinsonism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PD during life is based on clinical impression; neurodiagnostic testing is almost always unhelpful. While a clinical diagnosis of idiopathic PD may seem relatively simple, the accuracy of such a diagnosis can be as low as 75 percent when neuropathological examination is used as the diagnostic gold standard. On the other hand, diagnostic accuracy is increased to as high as 90 percent if patients are followed long-term by movement disorders specialists. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H105734443\">",
"       'Diagnostic accuracy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bradykinesia, plus one of the remaining two cardinal manifestations (tremor, rigidity), should be present in order to make the diagnosis of idiopathic PD. In addition, an excellent response to dopaminergic therapy is an important criterion for the diagnosis. Other clinical features that are supportive of the diagnosis are unilateral onset, presence of a rest tremor, and a persistent asymmetry throughout the course of the disease with the side of onset most affected. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"       \"Clinical manifestations of Parkinson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Features that are most useful for identifying patients with parkinsonism other than PD are the following (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Features suggesting an alternative diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Falls at presentation and early in disease",
"     </li>",
"     <li>",
"      Poor response to levodopa",
"     </li>",
"     <li>",
"      Symmetry at onset",
"     </li>",
"     <li>",
"      Rapid progression",
"     </li>",
"     <li>",
"      Lack of tremor",
"     </li>",
"     <li>",
"      Dysautonomia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While there are no diagnostic tests for PD, we suggest brain MRI scan to exclude structural lesions. Striatal dopamine transporter imaging (DaTscan) may also be useful for occasional patients for whom the clinical diagnosis is unclear. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ancillary tests'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'DaTscan'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/1\">",
"      Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/2\">",
"      Ahlskog JE. Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. Parkinsonism Relat Disord 2000; 7:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/3\">",
"      Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/4\">",
"      Louis ED, Levy G, C&ocirc;te LJ, et al. Clinical correlates of action tremor in Parkinson disease. Arch Neurol 2001; 58:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/5\">",
"      Jain S, Lo SE, Louis ED. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol 2006; 63:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/6\">",
"      Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/7\">",
"      Christine CW, Aminoff MJ. Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance. Am J Med 2004; 117:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/8\">",
"      Litvan I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 1997; 120 ( Pt 1):65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/9\">",
"      Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/10\">",
"      Quinn N. Parkinsonism--recognition and differential diagnosis. BMJ 1995; 310:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/11\">",
"      Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996; 47:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/12\">",
"      Verny M, Jellinger KA, Hauw JJ, et al. Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathol 1996; 91:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/13\">",
"      Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986; 36:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/14\">",
"      Manyam BV, Walters AS, Narla KR. Bilateral striopallidodentate calcinosis: clinical characteristics of patients seen in a registry. Mov Disord 2001; 16:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/15\">",
"      Ellie E, Julien J, Ferrer X. Familial idiopathic striopallidodentate calcifications. Neurology 1989; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/16\">",
"      Oliveira JR, Spiteri E, Sobrido MJ, et al. Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology 2004; 63:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/17\">",
"      Wang C, Li Y, Shi L, et al. Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis. Nat Genet 2012; 44:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/18\">",
"      Geschwind DH, Loginov M, Stern JM. Identification of a locus on chromosome 14q for idiopathic basal ganglia calcification (Fahr disease). Am J Hum Genet 1999; 65:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/19\">",
"      Volpato CB, De Grandi A, Buffone E, et al. 2q37 as a susceptibility locus for idiopathic basal ganglia calcification (IBGC) in a large South Tyrolean family. J Mol Neurosci 2009; 39:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/20\">",
"      Manyam BV. What is and what is not 'Fahr's disease'. Parkinsonism Relat Disord 2005; 11:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/21\">",
"      Koller WC, Cochran JW, Klawans HL. Calcification of the basal ganglia: computerized tomography and clinical correlation. Neurology 1979; 29:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/22\">",
"      Harrington MG, Macpherson P, McIntosh WB, et al. The significance of the incidental finding of basal ganglia calcification on computed tomography. J Neurol Neurosurg Psychiatry 1981; 44:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/23\">",
"      F&ouml;rstl H, Krumm B, Eden S, Kohlmeyer K. Neurological disorders in 166 patients with basal ganglia calcification: a statistical evaluation. J Neurol 1992; 239:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/24\">",
"      Reider-Groswasser I, Bornstein NM, Korczyn AD. Parkinsonism in patients with lucanar infarcts of the basal ganglia. Eur Neurol 1995; 35:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/25\">",
"      Peralta C, Werner P, Holl B, et al. Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. J Neural Transm 2004; 111:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/26\">",
"      Buchman AS, Leurgans SE, Nag S, et al. Cerebrovascular disease pathology and parkinsonian signs in old age. Stroke 2011; 42:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/27\">",
"      Mena MA, de Y&eacute;benes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 2006; 5:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/28\">",
"      Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988; 51:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/29\">",
"      Jankovic J, Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol 1987; 10:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/30\">",
"      Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/31\">",
"      Colosimo C, Pezzella FR. The symptomatic treatment of multiple system atrophy. Eur J Neurol 2002; 9:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/32\">",
"      Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 2004; 75:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/33\">",
"      Rossi P, Colosimo C, Moro E, et al. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol 2000; 43:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/34\">",
"      Merello M, Nouzeilles MI, Arce GP, Leiguarda R. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis. Mov Disord 2002; 17:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/35\">",
"      Suchowersky O, Reich S, Perlmutter J, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/36\">",
"      Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/37\">",
"      Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci 1991; 18:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/38\">",
"      Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/39\">",
"      Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/40\">",
"      Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 2000; 57:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/41\">",
"      Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/42\">",
"      Stern MB, Braffman BH, Skolnick BE, et al. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology 1989; 39:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/43\">",
"      Asato R, Akiguchi I, Masunaga S, Hashimoto N. Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy. J Neural Transm 2000; 107:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/44\">",
"      Konagaya M, Konagaya Y, Iida M. Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 1994; 57:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/45\">",
"      Yekhlef F, Ballan G, Macia F, et al. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm 2003; 110:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/46\">",
"      Seppi K, Schocke MF. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol 2005; 18:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/47\">",
"      Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/48\">",
"      Wang JJ, Lin WY, Lu CS, et al. Parkinson disease: diagnostic utility of diffusion kurtosis imaging. Radiology 2011; 261:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/49\">",
"      Seppi K, Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 2010; 20:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/50\">",
"      Mahlknecht P, Hotter A, Hussl A, et al. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. Neurodegener Dis 2010; 7:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/51\">",
"      Leh&eacute;ricy S, Sharman MA, Dos Santos CL, et al. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012; 27:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/52\">",
"      Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011; 10:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/53\">",
"      K&auml;gi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/54\">",
"      de la Fuente-Fern&aacute;ndez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012; 78:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/55\">",
"      Perlmutter JS, Eidelberg D. To scan or not to scan: DaT is the question. Neurology 2012; 78:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/56\">",
"      Tolosa E, Borght TV, Moreno E, DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord 2007; 22:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/57\">",
"      Teune LK, Bartels AL, de Jong BM, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010; 25:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/58\">",
"      Pavese N. PET studies in Parkinson's disease motor and cognitive dysfunction. Parkinsonism Relat Disord 2012; 18 Suppl 1:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/59\">",
"      Hellwig S, Amtage F, Kreft A, et al. [&sup1;���F]FDG-PET is superior to [&sup1;&sup2;&sup3;I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/60\">",
"      Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/61\">",
"      Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/62\">",
"      Stern MB. Transcranial ultrasound in Parkinson's disease. Lancet Neurol 2008; 7:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/63\">",
"      Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008; 7:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/64\">",
"      Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008; 7:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/65\">",
"      Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003; 60:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/66\">",
"      Stockner H, Schwingenschuh P, Djamshidian A, et al. Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease? Mov Disord 2012; 27:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/67\">",
"      Deeb J, Shah M, Muhammed N, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease. QJM 2010; 103:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/68\">",
"      Katzenschlager R, Lees AJ. Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 2004; 17:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26089/abstract/69\">",
"      Katzenschlager R, Zijlmans J, Evans A, et al. Olfactory function distinguishes vascular parkinsonism from Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:1749.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4904 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26089=[""].join("\n");
var outline_f25_30_26089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Essential tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H110046802\">",
"      SWEDD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Corticobasal degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Multiple system atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Progressive supranuclear palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105734326\">",
"      Idiopathic basal ganglia calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other neurodegenerative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Secondary parkinsonism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Drug-induced parkinsonism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Response to dopaminergic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Features suggesting an alternative diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105734443\">",
"      Diagnostic accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ancillary tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Conventional MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Newer MRI techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - DaTscan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84789572\">",
"      - PET",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Olfactory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Autonomic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/1/13340\" title=\"table 1\">",
"      Disorders that can mimic PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/56/37771\" title=\"table 2\">",
"      Parkinson vs essential tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/34/2603\" title=\"table 3\">",
"      Hoehn and Yahr scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5354?source=related_link\">",
"      Corticobasal degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=related_link\">",
"      Diseases of the central nervous system caused by prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29832?source=related_link\">",
"      Huntington disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=related_link\">",
"      Multiple system atrophy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6870?source=related_link\">",
"      Multiple system atrophy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4277?source=related_link\">",
"      Nonpharmacologic management of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=related_link\">",
"      Normal pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=related_link\">",
"      Overview of tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=related_link\">",
"      Parkinson disease dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=related_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26090?source=related_link\">",
"      Progressive supranuclear palsy (PSP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_30_26090="Progressive supranuclear palsy (PSP)";
var content_f25_30_26090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Progressive supranuclear palsy (PSP)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26090/contributors\">",
"     Stewart A Factor, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26090/contributors\">",
"     Christine Doss Esper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26090/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/30/26090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/30/26090/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/30/26090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H90507646\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of parkinsonism (ie, tremor, bradykinesia, rigidity, and postural instability) can be prominent in neurodegenerative disorders other than idiopathic Parkinson disease, particularly in atypical parkinsonian disorders, which include corticobasal degeneration, multiple system atrophy, and progressive supranuclear palsy.",
"   </p>",
"   <p>",
"    Progressive supranuclear palsy (PSP), also known as Steele Richardson Olszewski syndrome, is an uncommon but not rare parkinsonian syndrome. Characteristic features of PSP include vertical supranuclear gaze palsy and postural instability with unexplained falls. This topic will review specifically the clinical aspects of PSP. Other neurodegenerative parkinsonian syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of Parkinson disease\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5354?source=see_link\">",
"     \"Corticobasal degeneration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=see_link\">",
"     \"Multiple system atrophy: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5944866\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1964, Steele, Richardson, and Olszewski were the first to describe PSP when their seminal report of nine cases with autopsy confirmation was published [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result of their pioneering work, some have referred to the disease as the Steele-Richardson-Olszewski syndrome. Since that time, hundreds of additional cases have been recorded, and the disease is now a well-recognized atypical parkinsonian syndrome (or Parkinson-plus disorder). As originally described, PSP is characterized by progressive supranuclear ophthalmoplegia, gait disorder and postural instability, dysarthria, dysphagia, rigidity, and frontal cognitive disturbance. The authors of the original report speculated whether PSP was a primary disorder of the central nervous system or a post-infectious (viral) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/2\">",
"     2",
"    </a>",
"    ]. The consistent pathologic features of PSP consist of neuronal loss, globose neurofibrillary tangles, and gliosis mainly in the basal ganglia, cerebellum, brainstem, and to a lesser extent, the cerebral cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/3\">",
"     3",
"    </a>",
"    ]. A universally accepted set of diagnostic criteria for PSP was proposed in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H90507700\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PSP is now recognized to encompass a number of phenotypic variants. The two most common are Richardson syndrome (the classic form of PSP) and PSP-parkinsonism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5944873\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive supranuclear palsy is the most common of the degenerative forms of atypical parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. An early study found that the population",
"    <strong>",
"     prevalence",
"    </strong>",
"    of PSP was 1.39 per 100,000 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/7\">",
"     7",
"    </a>",
"    ]. Although this study has been criticized because of methodologic flaws, it established that PSP was not as rare as had previously been believed. Later reports from other countries demonstrated an even higher prevalence, 6.4 per 100,000 in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/6,8\">",
"     6,8",
"    </a>",
"    ] and 5.8 per 100,000 in western Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early studies found that the annual",
"    <strong>",
"     incidence",
"    </strong>",
"    rates of PSP ranged from 0.3 to 0.4 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. However, a study published in 1999 reported an annual incidence of 1.1 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. The greater incidence found in later studies may be a result of better case ascertainment due in part to increased recognition of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/5\">",
"     5",
"    </a>",
"    ]. The annual incidence increases with age from 1.7 cases per 100,000 at ages 50 to 59 years to 14.7 per 100,000 at 80 to 89 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/14\">",
"     14",
"    </a>",
"    ]. The true incidence may be higher still with the subsequent discovery that several phenotypes of PSP exist. (See",
"    <a class=\"local\" href=\"#H90508451\">",
"     'Variant phenotypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mean age of onset for PSP is approximately 62 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/7,15\">",
"     7,15",
"    </a>",
"    ], which is older than in idiopathic Parkinson disease. Virtually no cases of PSP have been reported in patients younger than age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/2\">",
"     2",
"    </a>",
"    ]. The original clinical report noted a strong male predominance of approximately eight to one [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/1\">",
"     1",
"    </a>",
"    ]. However, later reports have been mixed. Six series found a male predominance, [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/2,7,16-19\">",
"     2,7,16-19",
"    </a>",
"    ], two a female predominance, [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/15,20\">",
"     15,20",
"    </a>",
"    ], and one an even ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 121 patients with probable PSP, there were no significant male-female differences for a variety of disease measures including age at onset, clinical characteristics, and disease duration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90508640\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no proven risk factors for the development of PSP except age. Some studies have reported that education level or environmental exposures may be associated with increased risk, but the findings have been conflicting. An early case-control study found that patients with PSP (n = 50) were more likely than controls to have completed high school and college [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/23\">",
"     23",
"    </a>",
"    ]. However, a subsequent study from the same investigators with 113 patients found that lower levels of education were associated with an increased risk of PSP, whereas no history of elevated toxic exposure was detected [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/24\">",
"     24",
"    </a>",
"    ]. Two small case series reported environmental exposure to organic solvents in 12 of 13 patients with PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H439178170\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although PSP is considered to be a sporadic disorder, some observations suggest that genetic susceptibility has a role:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a few reports of a positive family history of PSP and other types of parkinsonism [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. However, these are distinctly rare.",
"     </li>",
"     <li>",
"      A genome-wide association study reported an increased risk of PSP for two independent variants of microtubule-associated protein tau gene (MAPT) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/30\">",
"       30",
"      </a>",
"      ]. In addition, the study found an increased risk for several additional genes (STX6, EIF2AK3, and MOBP), the significance of which is unclear.",
"     </li>",
"     <li>",
"      Several studies have demonstrated an overrepresentation of the H1 haplotype and A0 allele of the MAPT in PSP [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. This has implied biological plausibility, since the tau protein is abundant in the brains of subjects with PSP. However, the H1 haplotype is also more common in patients with Parkinson disease compared with controls, even though tau accumulation and aggregation is not a part of the pathological picture of Parkinson disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/34\">",
"       34",
"      </a>",
"      ]. Hence, the meaning of this finding still needs to be clarified.",
"     </li>",
"     <li>",
"      A case-control study reported that first-degree relatives of patients with PSP performed worse than normal controls on an idiopathic Parkinson disease test battery that evaluated motor function, olfaction, and mood [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/35\">",
"       35",
"      </a>",
"      ]. The authors speculated that testing may detect an asymptomatic carrier state or risk for PSP, or a subclinical effect of a shared environmental exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5944880\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the most common &ldquo;classic&rdquo; phenotype of PSP, known as Richardson phenotype or Richardson syndrome, the most frequent initial feature of PSP is a disturbance of gait resulting in falls. Supranuclear ophthalmoparesis or plegia is the hallmark of PSP (hence the name of the disease). Dysarthria, dysphagia, pseudobulbar palsy, rigidity, frontal cognitive abnormalities, and sleep disturbances are additional common clinical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3595923\">",
"    <span class=\"h2\">",
"     Postural instability and falls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with classic PSP have a stiff and broad-based gait, with a tendency to have their knees and trunk extended (as opposed to the flexed posture of idiopathic Parkinson disease), and arms slightly abducted. They demonstrate impulsivity, probably from the frontal lobe involvement, and hence tend to lurch and stagger. Step length is varied, as is base width. Instead of turning en bloc as seen in Parkinson disease, they tend to pivot quickly, further compromising their balance and indicating an inability to take protective measures. When they fall, it is usually backwards. Over the course of the illness, such falls can result in a spectrum of injuries that include bruises, lacerations,",
"    <span class=\"nowrap\">",
"     bone/skull",
"    </span>",
"    fractures, subdural hematomas, and sometimes death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/36\">",
"     36",
"    </a>",
"    ]. When postural instability and falls are the only features of the disease, an abnormal response to the postural reflex testing (pulling the patient gently but firmly by the shoulders from behind to see if he or she staggers backward uncontrollably) may be the only abnormality in a patient's examination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402970\">",
"    <span class=\"h2\">",
"     Oculomotor findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supranuclear ophthalmoparesis or plegia is the hallmark of PSP &ndash; hence the name of the disease &ndash; but it may take as long as ten years to develop. The average is three to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/38\">",
"     38",
"    </a>",
"    ]. This distinctive ocular finding is first noted as slowing of vertical saccades, followed by a limitation of saccadic range. Concomitant limitation of lateral gaze is often present but is less prominent. Pursuit movements of the eyes are slow, jerky, and hypometric with unstable fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/39\">",
"     39",
"    </a>",
"    ]. The ophthalmoparesis is initially overcome by the oculocephalic (Doll&rsquo;s eyes) maneuver, but with disease progression and brainstem involvement, vestibuloocular reflexes may be lost.",
"   </p>",
"   <p>",
"    Other oculomotor findings in PSP include saccadic intrusions into fixation (\"square wave jerks\"), loss of optokinetic nystagmus (particularly in the vertical direction), loss of convergence, blepharospasm, and eyelid-opening apraxia.",
"   </p>",
"   <p>",
"    The combination of rare blinking, facial dystonia, and gaze abnormalities leads to the development of a classic facial expression of perpetual surprise or astonishment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ]. Vertical gaze impairment commonly leads to problems with reading, spilling food while eating, and tripping while walking [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402977\">",
"    <span class=\"h2\">",
"     Motor involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigidity in patients with PSP is usually more apparent in axial than limb muscles, especially the neck and upper trunk. It can be demonstrated on examination by resistance to passive movement of the neck. Retrocollis was emphasized as an important physical finding in the original description of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/1\">",
"     1",
"    </a>",
"    ], but is now estimated to occur in less than 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition to the retrocollis, other types of dystonia include blepharospasm, and more rarely limb or hemidystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Apraxia of eyelid opening can be mistaken for blepharospasm but is distinguished by the absence of forced closure of the eyes.",
"   </p>",
"   <p>",
"    The parkinsonism of PSP differs from that of idiopathic Parkinson disease in ways other than the early falling. Resting tremor is rare in PSP and rigidity tends to be much more pronounced in the neck than the limbs. As mentioned, unsteady gait and freezing of gait appear early in the course of PSP compared with Parkinson disease. Bradykinesia with marked micrographia is the primary feature of parkinsonism in PSP. In addition, an absent, poor, or rapidly waning response to levodopa is a characteristic feature of PSP. A few patients with PSP show a moderate response to dopaminergic agents in the early stages of disease, but most do not [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ]. In some, the gait and balance problems actually worsen with levodopa. Other clinical features of PSP include stuttering and palilalia (the involuntary repetition of words or phrases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402984\">",
"    <span class=\"h2\">",
"     Cognitive and behavioral abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuropsychological profile of PSP primarily involves frontal lobe dysfunction. The patients manifest impaired abstract thought, decreased verbal fluency, motor perseveration, and frontal behavioral disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of early and severe frontal cognitive (executive) deficits is a common finding in PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Executive dysfunction may be the presenting symptom of PSP in some patients and is characteristic of the later stages of the disease. In a cohort of 311 PSP patients, global cognition was impaired in approximately 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/46\">",
"     46",
"    </a>",
"    ], while impairment for a single or multiple domains was observed in 40 percent each and frontal impairment was observed in 62 percent. Cognitive impairment was seen in the early stages in 50 percent. Ideomotor apraxia may be a rare manifestation of PSP, although it is more common and severe in patients with corticobasal degeneration, a PSP look-alike [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavioral abnormalities are also common in patients with PSP. In a case series of 22 patients with PSP, the most common behavioral symptoms were apathy (91 percent), disinhibition (36 percent), dysphoria (18 percent), and anxiety (18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/48\">",
"     48",
"    </a>",
"    ]. One study of 188 patients with PSP demonstrated depression in 50 percent and anxiety in 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/49\">",
"     49",
"    </a>",
"    ], while another study of 74 patients with PSP reported obsessive compulsive symptoms in 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pseudobulbar palsy is another characteristic feature of PSP. Emotional incontinence is much less common than in other forms of pseudobulbar palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/2\">",
"     2",
"    </a>",
"    ], but patients with PSP commonly manifest the characteristic hoarse groaning voice along with moaning. The face is stiff, immobile, and deeply furrowed (the look of surprise) due to dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/2\">",
"     2",
"    </a>",
"    ]. About one-third of patients with PSP develop pyramidal signs, including hyperreflexia and Babinski signs. Facial and jaw jerks are exaggerated. The tongue is tightly contracted and movements are slow. Spastic dysarthria, dysphonia, and dysphagia are profound in the middle to later stages of disease. Speech perseveration and anomia, but not true aphasia, are also usually observed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402991\">",
"    <span class=\"h2\">",
"     Sleep disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early or late insomnia and difficulties in maintaining sleep have all been reported in patients with PSP. Polysomnographic evaluation of 10 patients with moderate to severe PSP revealed marked sleep abnormalities, all with significant periods (two to six hours) of insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/51\">",
"     51",
"    </a>",
"    ]. Marked rigidity may result in the inability to remain comfortable in bed, further contributing to the sleep complaints.",
"   </p>",
"   <p>",
"    In contrast, rapid eye movement sleep behavior disorder (RBD) is infrequently associated with PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/52\">",
"     52",
"    </a>",
"    ]. This negative finding, similar to the case of preserved olfaction (see",
"    <a class=\"local\" href=\"#H20105117\">",
"     'Potential disease markers'",
"    </a>",
"    below) can be helpful in differentiating PSP, a tau disorder, from Parkinson disease and multiple system atrophy, both of which are synucleinopathies and commonly demonstrate symptoms of RBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90508451\">",
"    <span class=\"h2\">",
"     Variant phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;After four-plus decades of studying PSP, it has become clear that the disease has at least four distinct clinical phenotypes. These are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Richardson syndrome (or phenotype), the classic form of PSP",
"     </li>",
"     <li>",
"      PSP-parkinsonism",
"     </li>",
"     <li>",
"      PSP-pure akinesia",
"     </li>",
"     <li>",
"      PSP-primary progressive freezing gait",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 103 patients with pathologically-confirmed PSP, there were 56 patients (54 percent) with the Richardson phenotype, 33 patients (32 percent) with PSP-parkinsonism, and 14 patients (14 percent) who could not be classified into either of the two phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/53\">",
"     53",
"    </a>",
"    ]. Cases of Richardson syndrome were characterized by early onset of postural instability and falls, supranuclear vertical gaze palsy, and cognitive dysfunction. Cases of PSP-parkinsonism were characterized by asymmetric onset of limb symptoms, tremor, and a moderate initial therapeutic response to levodopa. These cases were frequently confused with idiopathic Parkinson disease. Another pathologic report found that Richardson syndrome was associated with greater amount of frontal cortical atrophy, particularly frontal pole and inferior frontal gyrus, compared with PSP-parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The third phenotype is a syndrome of PSP-pure akinesia, sometimes referred to as pure akinesia with gait freezing. This disorder was first described in the Japanese literature [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/55\">",
"     55",
"    </a>",
"    ], but is well described in other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/56\">",
"     56",
"    </a>",
"    ]. PSP-pure akinesia is characterized by akinesia of gait, handwriting, and speech, as manifest by micrographia, and excessively rapid, hypophonic speech that is poorly intelligible (festinating speech). Gait can be shuffling and slow with or without freezing. Tremor, rigidity, dementia, and a positive response to levodopa are notably absent in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/57\">",
"     57",
"    </a>",
"    ]. Abnormalities of the eyelids (blepharospasm or apraxia of eyelid opening) and extraocular movements can be seen with careful examination, although in some cases they can only be elicited by using quantitative measures. Eye movement abnormalities eventually occur in most, if not all, patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/57\">",
"     57",
"    </a>",
"    ]. Some cases of PSP-pure akinesia have been established through postmortem studies to be an atypical presentation for PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/56,58,59\">",
"     56,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary progressive freezing gait (PPFG) is a syndrome with several causes that is characterized by early (initial feature or frequently present in the first year) gait freezing, bradykinesia, rigidity, and unresponsiveness to dopaminergic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/60\">",
"     60",
"    </a>",
"    ]. In one report, several patients with primary progressive freezing gait eventually developed the classical eye movements of PSP after nine years. One such case has been diagnosed pathologically with PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/61\">",
"     61",
"    </a>",
"    ]. However, this syndrome can be the result of several underlying diseases, as shown in a prospective study of nine patients with primary progressive freezing gait syndrome who were followed for 6 to 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/62\">",
"     62",
"    </a>",
"    ]. Three were ultimately diagnosed clinically with PSP, one was diagnosed on clinical grounds with corticobasal degeneration, and one patient each was diagnosed pathologically with dementia with Lewy bodies and pallidonigroluysian degeneration.",
"   </p>",
"   <p>",
"    The atypical presentations of PSP (eg, PSP-parkinsonism, PSP-pure akinesia, and PSP-primary progressive freezing gait) do not generally meet clinical research criteria for possible PSP, mainly because falling and eye movement abnormalities occurred after one year of disease, whereas diagnostic criteria for PSP (",
"    <a class=\"graphic graphic_table graphicRef65437 \" href=\"UTD.htm?4/55/4989\">",
"     table 1",
"    </a>",
"    ) require the presence of vertical supranuclear palsy and prominent postural instability with falls in the first year of disease onset as discussed below. (See",
"    <a class=\"local\" href=\"#H90507700\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional rare variants of PSP that have considerable clinical overlap with other neurodegenerative disorders are recognized by some experts because tau pathology in a pattern that is typical of PSP has been found in some patients with these syndromes. These additional PSP variants include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PSP-corticobasal degeneration, characterized by progressive asymmetric apraxia, dystonia, cortical sensory loss, alien limb syndrome, levodopa unresponsiveness, and tau pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Progressive nonfluent aphasia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/64-66\">",
"       64-66",
"      </a>",
"      ], a syndrome that is more commonly seen as a manifestation of frontotemporal lobe dementias",
"     </li>",
"     <li>",
"      PSP with pallidonigroluysian degeneration [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H402998\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with PSP, neuroimaging studies using CT and MRI of the brain demonstrate generalized and brainstem atrophy, particularly involving the midbrain. The radiologic &ldquo;hummingbird sign&rdquo; (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78365 \" href=\"UTD.htm?42/3/43056\">",
"     image 1",
"    </a>",
"    ), also called the &ldquo;penguin silhouette&rdquo; sign, results from the prominent midbrain atrophy with a relatively preserved pons, resembling a hummingbird or penguin in silhouette on midsagittal MRI of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Superior cerebellar peduncle atrophy is common in PSP and correlates with disease duration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The application of volumetric measures to assess the specificity of",
"    <span class=\"nowrap\">",
"     brainstem/midbrain",
"    </span>",
"    atrophy observed in SPS is discussed below. (See",
"    <a class=\"local\" href=\"#H20105117\">",
"     'Potential disease markers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5944894\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross examination of the brain in patients with PSP reveals midbrain and, to a lesser extent, cerebral cortical atrophy, hypopigmentation of the substantia nigra and locus ceruleus, and enlargement of the third ventricle and Sylvian aqueduct [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/2,72\">",
"     2,72",
"    </a>",
"    ]. Microscopic findings in PSP are distinctive and prominent. The most consistent sites of pathology are in the basal ganglia, particularly in the substantia nigra, subthalamic nucleus, cerebellum, and internal globus pallidus, in addition to the oculomotor complex, periaqueductal gray matter, superior colliculi, basis pontis, dentate nucleus, and prefrontal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/72\">",
"     72",
"    </a>",
"    ]. Involvement of the cerebral cortex is also increasingly recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/20\">",
"     20",
"    </a>",
"    ]. PSP pathology has also been reported in the spinal cord, explaining the possible urinary disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic characteristics of PSP include neuronal loss, gliosis, and the presence of tau-positive filamentous inclusions in specific anatomic areas involving astrocytes, oligodendrocytes, and neurons (",
"    <a class=\"graphic graphic_picture graphicRef66637 \" href=\"UTD.htm?35/0/35849\">",
"     picture 1",
"    </a>",
"    ). Tau cytoplasmic inclusions in surviving neurons, known as globose neurofibrillary tangles, are classically described in PSP, but are not specific to PSP. Neurofibrillary tangles are found also in Alzheimer disease, postencephalitic parkinsonism, dementia pugilistica, and the parkinsonism-dementia complex of Guam. Tau-positive inclusions commonly seen in oligodendrocytes are called &ldquo;coiled bodies.&rdquo; When seen in astrocytes, the tau-positive inclusions are called \"tufted astrocytes\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/74\">",
"     74",
"    </a>",
"    ]. Involvement of all three cell types makes PSP unique among the tauopathies.",
"   </p>",
"   <p>",
"    Ultrastructurally, the neurofibrillary tangles of PSP are composed of single straight filaments, in contrast to the paired helical filaments that predominate in Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/75\">",
"     75",
"    </a>",
"    ]. In other neurodegenerative diseases with tau pathology, the tangles are flame-shaped; in PSP, they are predominantly of the globose (globular) type. Some reports have suggested a remarkable heterogeneity for PSP pathology, particularly with regard to the overlap between PSP and Alzheimer disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/76\">",
"     76",
"    </a>",
"    ] and PSP and corticobasal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major structural element of the neurofibrillary tangles in PSP is an abnormally phosphorylated tau protein. Tau is a protein that is involved in axonal transport and stabilization of neuronal microtubules. It is thought that abnormal phosphorylation of tau interferes with microtubule function, impairs axonal transport, and leads to tau aggregation into neurofibrillary tangles. Normal brain tau contains six isoforms that are generated by the alternative splicing of a single tau gene on chromosome 17. Mutations in the tau gene have been associated with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/79\">",
"     79",
"    </a>",
"    ]. Studies have emphasized that PSP shares degree of genotypic overlap with corticobasal degeneration, as both disorders are more frequently associated with homozygosity for the H1 tau haplotype (an association also seen in Parkinson disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/78,80\">",
"     78,80",
"    </a>",
"    ]. Furthermore, a genome wide association study (see",
"    <a class=\"local\" href=\"#H439178170\">",
"     'Genetic susceptibility'",
"    </a>",
"    above) confirmed that the risk of PSP is associated with two independent variants of the microtubule-associated protein tau gene (MAPT)",
"    <em>",
"     ,",
"    </em>",
"    one which influences MAPT brain expression [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, isoforms common to both PSP and corticobasal degeneration tauopathies are aggregates of the four-repeat microtubule-binding domains that occur because of splicing of exon 10, in contrast to other tau disorders, where the three-repeat form dominates in the aggregates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/77\">",
"     77",
"    </a>",
"    ]. The normal ratio of three and four-repeat tau is approximately equal. &nbsp;",
"   </p>",
"   <p>",
"    Neurochemical studies indicate that the degenerative process in PSP involves dopaminergic neurons that innervate the striatum, as well as cholinergic and gamma-aminobutyric acid (GABA) interneurons and efferent neurons, respectively, in the striatum and other basal ganglionic and brainstem nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Postmortem studies of patients with PSP have demonstrated a marked reduction in striatal D2 receptors, whereas the striatal D1 receptors are relatively spared [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In the brainstem, cholinergic neurons have been found to degenerate in the Edinger-Westphal nucleus, rostral interstitial nucleus of Cajal, the medial longitudinal fasciculus, superior colliculus, and the pedunculopontine nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Also, a reduction in the acetylcholine vesicular transporter has been found to potentially differentiate PSP from other types of neurodegenerative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/87\">",
"     87",
"    </a>",
"    ]. Glutamate is increased in the striatum, pallidum, nucleus accumbens, and occipital and temporal cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/88\">",
"     88",
"    </a>",
"    ]. One postmortem study demonstrated a 50 to 60 percent reduction of the GABAergic basal ganglia output neurons, which may, in part, explain the poor response to dopaminergic therapy in most patients who have this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/89\">",
"     89",
"    </a>",
"    ]. The observation that multiple neurotransmitters, particularly dopamine and acetylcholine, are affected in PSP suggests that PSP is not a primary \"neurotransmitter\" disease, but a disorder in which multiple subpopulations of neurons degenerate with neurotransmitter availability diminished as a secondary effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90507634\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PSP is currently based upon the clinical features. No laboratory or imaging studies are diagnostic. Neuropathologic examination remains the gold standard for its definitive diagnosis. The pathologic diagnosis of PSP is based upon the identification of neurofibrillary tangles in a distribution considered typical for PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90507700\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1996, the National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP, Inc. (SPSP) proposed a set of diagnostic criteria for PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/4\">",
"     4",
"    </a>",
"    ]. The NINDS-SPSP criteria (",
"    <a class=\"graphic graphic_table graphicRef65437 \" href=\"UTD.htm?4/55/4989\">",
"     table 1",
"    </a>",
"    ) specify mandatory inclusion criteria for possible, probable, and definite PSP as well as mandatory exclusion criteria and supportive criteria for the diagnosis.",
"   </p>",
"   <p>",
"    Mandatory inclusion criteria are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possible PSP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gradually progressive disorder",
"     </li>",
"     <li>",
"      Onset at age 40 or later",
"     </li>",
"     <li>",
"      Either vertical (upward or downward gaze) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset.",
"     </li>",
"     <li>",
"      No evidence of other diseases that could explain the foregoing features, as indicated by mandatory exclusion criteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Probable PSP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gradually progressive disorder",
"     </li>",
"     <li>",
"      Onset at age 40 or later",
"     </li>",
"     <li>",
"      Vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset",
"     </li>",
"     <li>",
"      No evidence of other disease that could explain the foregoing features, as indicated by mandatory exclusion criteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definite PSP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinically probable or possible PSP and histopathologic evidence of typical PSP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mandatory exclusion criteria are the following [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent history of encephalitis",
"     </li>",
"     <li>",
"      Alien limb syndrome, cortical sensory deficits, focal frontal or temporoparietal atrophy",
"     </li>",
"     <li>",
"      Hallucinations or delusions unrelated to dopaminergic therapy",
"     </li>",
"     <li>",
"      Cortical dementia of Alzheimer type",
"     </li>",
"     <li>",
"      Prominent, early cerebellar symptoms or prominent, early unexplained dysautonomia (marked hypotension and urinary disturbances)",
"     </li>",
"     <li>",
"      Severe asymmetric parkinsonian signs",
"     </li>",
"     <li>",
"      Neuroradiologic evidence of relevant structural abnormality",
"     </li>",
"     <li>",
"      Whipple disease, confirmed by polymerase chain reaction, if indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive criteria for PSP are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symmetric akinesia or rigidity, proximal more than distal",
"     </li>",
"     <li>",
"      Abnormal neck posture, especially retrocollis",
"     </li>",
"     <li>",
"      Poor or absent response of parkinsonism to levodopa therapy",
"     </li>",
"     <li>",
"      Early dysphagia and dysarthria",
"     </li>",
"     <li>",
"      Early onset of cognitive impairment including at least two of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Apathy",
"     </li>",
"     <li>",
"      Impairment in abstract thought",
"     </li>",
"     <li>",
"      Decreased verbal fluency",
"     </li>",
"     <li>",
"      Utilization or imitation behavior",
"     </li>",
"     <li>",
"      Frontal release signs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 1996 NINDS-SPSP workshop recommended testing the response of the parkinsonism to levodopa therapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    <span class=\"nowrap\">",
"     25/250",
"    </span>",
"    mg administered three times a day for at least two months [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/4\">",
"     4",
"    </a>",
"    ]. The response to levodopa is considered poor if the extrapyramidal features do not show marked improvement, or if the therapeutic effect is transient (ie, lasts less than a year). An excellent response to dopaminergic therapy is an important supportive feature for establishing the diagnosis of Parkinson disease, as discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis of Parkinson disease\", section on 'Response to dopaminergic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NINDS-SPSP clinical criteria for diagnosing PSP have a high specificity and positive predictive value, but due to varied clinical presentations and absence of classic signs in the early disease stages, an early diagnosis is not always possible.",
"   </p>",
"   <p>",
"    There are no consensus guidelines for the clinical diagnosis of the PSP variants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the variant forms of PSP have significant overlap, they can be distinguished in some cases by differences in clinical phenotype. To reiterate (see",
"    <a class=\"local\" href=\"#H90508451\">",
"     'Variant phenotypes'",
"    </a>",
"    above): &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Richardson syndrome, the classic form of PSP, is characterized by early onset of postural instability and falls, supranuclear vertical gaze palsy, and cognitive dysfunction. Axial rigidity is more prominent than appendicular rigidity and retrocollis is often present.",
"     </li>",
"     <li>",
"      PSP-parkinsonism is characterized by asymmetric onset of limb symptoms, tremor, and a moderate initial therapeutic response to levodopa. Falls and cognitive impairment occur later in PSP-parkinsonism than in Richardson syndrome.",
"     </li>",
"     <li>",
"      PSP-pure akinesia is characterized by akinesia of gait, handwriting, and speech.",
"     </li>",
"     <li>",
"      PSP-progressive freezing gait is characterized by early (initial feature or frequently present in the first year) gait freezing, bradykinesia, rigidity, and unresponsiveness to dopaminergic medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20105117\">",
"    <span class=\"h2\">",
"     Potential disease markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established laboratory or imaging markers for the diagnosis of PSP. Routine analysis of blood and urine are normal. Routine investigations of cerebrospinal fluid (CSF) in PSP are also normal.",
"   </p>",
"   <p>",
"    Potential markers of PSP include levels of neurotransmitters and brain metabolites in the CSF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The level of CSF homovanillic acid, the main catabolic product of central nervous system dopamine, was subnormal in 14 cases of PSP with obvious parkinsonian symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/91\">",
"       91",
"      </a>",
"      ]. Reports of dopamine metabolism in PSP indicate that abnormalities are correlated to the parkinsonian features and detectable only in advanced stages [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/2\">",
"       2",
"      </a>",
"      ]. CSF levels of 5-hydroxyindoleacetic acid and norepinephrine have been documented as normal.",
"     </li>",
"     <li>",
"      One study found that CSF levels of tau protein were significantly lower in PSP than in patients with corticobasal degeneration and in healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/92\">",
"       92",
"      </a>",
"      ]. Both extended (55 kDa) and truncated (33 kDa) forms of tau are recognized in the CSF, and one report observed that the ratio of the truncated to extended CSF tau forms in patients with a clinical diagnosis of PSP was significantly lower than in normal controls and patients with other neurodegenerative conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted earlier (see",
"    <a class=\"local\" href=\"#H402998\">",
"     'Neuroimaging'",
"    </a>",
"    above), neuroimaging of patients with PSP using CT and MRI of the brain demonstrates generalized atrophy and brainstem atrophy, most pronounced in the midbrain. A number of small studies have used volumetric measures in an attempt to assess the specificity of this pattern of atrophy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report found that the anterior-posterior diameter of the suprapontine midbrain was significantly lower in patients with PSP than in patients with idiopathic Parkinson disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/94\">",
"       94",
"      </a>",
"      ]. Another study found that the average midbrain area of patients with PSP (56 mm",
"      <sup>",
"       2",
"      </sup>",
"      ) was significantly lower than in patients with Parkinson disease (103 mm",
"      <sup>",
"       2",
"      </sup>",
"      ) or multiple system atrophy-parkinsonism (97 mm",
"      <sup>",
"       2",
"      </sup>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/95\">",
"       95",
"      </a>",
"      ]. The ratio of midbrain to pontine area was found to reliably differentiate the three disorders.",
"     </li>",
"     <li>",
"      In a third report, midbrain atrophy was assessed by measurement of midsagittal area of the midbrain and pons. Compared with matched controls, the ratio of the sagittal pons area to midbrain area",
"      <span class=\"nowrap\">",
"       (P/M",
"      </span>",
"      ratio) was significantly higher in the PSP group [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies have suggested that the magnetic resonance parkinsonism index (MRPI) can distinguish patients with PSP from those with Parkinson disease and other atypical parkinsonian syndromes such as multiple system atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/97-99\">",
"       97-99",
"      </a>",
"      ]. The MRPI requires measurement of the area of the pons (P) and midbrain (M) and width of the middle cerebellar peduncle (MCP) on sagittal T1-weighted MRI and the width of the superior (SCP) on coronal MRI. The index is calculated from the formula MRPI =",
"      <span class=\"nowrap\">",
"       (P/M)",
"      </span>",
"      &times;",
"      <span class=\"nowrap\">",
"       (MCP/SCP).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the utility of these methods for the diagnosis of PSP in clinical practice remains to be established [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) scanning reveals decreased glucose metabolism in the midbrain as the earliest sign of PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/101\">",
"     101",
"    </a>",
"    ], followed by decreased metabolic activity in the caudate, putamen, and prefrontal cortex as the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. PET measures of striatal dopamine D2 receptor density using 11C-raclopride showed a 24 percent reduction in D2 density in the caudate and 9 percent reduction in the putamen of patients with PSP, but this finding has also been observed with other atypical parkinsonian syndromes as well [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H18#H18\">",
"     \"Diagnosis of Parkinson disease\", section on 'DaTscan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although brainstem auditory evoked potentials (BAER) and the blink reflex to an electrical stimulus are normal in PSP, there is an absence of the orbicularis oculi response in patients with PSP exhibiting a mentalis response to electrical stimulation of the median nerve. This finding differentiates PSP from all other parkinsonian syndromes, in which simultaneous responses of the orbicularis oculi and mentalis muscles are present after median nerve electrical stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longitudinal electro-oculographic recordings may help to distinguish PSP from other parkinsonian syndromes at early stages [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/107\">",
"     107",
"    </a>",
"    ]. Patients with PSP have normal latency but decreased saccade amplitude and velocity, whereas the opposite is observed in patients with corticobasal degeneration. Many of these electrophysiologic tests have been used for research purposes and are not generally available.",
"   </p>",
"   <p>",
"    The relative preservation of olfaction in PSP can help distinguish PSP from Parkinson disease, which is characterized by hyposmia early in the course. This is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnosis of Parkinson disease\", section on 'Olfactory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5944901\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PSP by common clinical symptoms and signs is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef53679 \" href=\"UTD.htm?38/45/39643\">",
"     table 2",
"    </a>",
"    ). The disorders that are the most difficult to differentiate from PSP are the other neurodegenerative parkinsonian disorders such as idiopathic Parkinson disease, corticobasal degeneration, multiple system atrophy, and dementia with Lewy bodies, as well as vascular parkinsonism. Patients with corticobasal degeneration almost always present with asymmetric signs, whereas in PSP they are usually but not always symmetric. The development of cortical sensory features, ideomotor apraxia, myoclonus, severe dystonia, and increased latency of saccades, should suggest a diagnosis of corticobasal degeneration. Multiple system atrophy is considered in younger patients and in the presence of severe autonomic signs or cerebellar disturbances. Nevertheless, these disorders overlap enough that clinical differentiation may be difficult, especially in the early course of illness.",
"   </p>",
"   <p>",
"    PSP and multiple system atrophy are the most likely causes of unexplained postural instability and falls occurring within the first year of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ]. Instability and falls in multiple system atrophy are usually present when patients already exhibit autonomic disturbances, although this may not be the case in the striatonigral degeneration or parkinsonian form of multiple system atrophy, in which autonomic signs occur later [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/108\">",
"     108",
"    </a>",
"    ]. Instability or falls may develop in patients with corticobasal degeneration in the first year, particularly when the first symptom affects a leg [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. However, falls may occur early in dementia with Lewy bodies, usually in association with significant cognitive disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ]. In a case series of 58 patients diagnosed with PSP, evidence of a multi-infarct state by CT, MRI, or autopsy was found in 19 patients (33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/109\">",
"     109",
"    </a>",
"    ]. Other incorrect diagnoses that are often assigned to elderly patients who fall include vestibulopathy, myelopathy, basilar artery ischemia, cardiac syncope, and epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although supranuclear gaze palsy is a key feature in diagnosing PSP, it may occasionally be present in other disorders, such as dementia with Lewy bodies, Alzheimer disease, idiopathic Parkinson disease, vascular parkinsonism, multiple system atrophy, Creutzfeldt-Jakob disease, Whipple disease, or corticobasal degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37,108\">",
"     37,108",
"    </a>",
"    ]. In PSP, the vertical supranuclear palsy precedes the development of the horizontal gaze palsy, but in corticobasal degeneration, ocular motor apraxia usually precedes the supranuclear gaze palsy, which usually affects both the horizontal and vertical gaze [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ]. The saccades in corticobasal degeneration have increased latency but normal speed, and are similarly affected in the vertical and horizontal plane, whereas in multiple system atrophy, the saccades have normal speed and latency. Blink rate, diminished in idiopathic Parkinson disease and multiple system atrophy, is usually less impaired in PSP. In addition, the upward gaze palsy, which may be the first indication of an ocular motor abnormality, should be differentiated from the limitation of upward gaze observed in &ldquo;normal&rdquo; elderly patients, in whom saccades have normal speed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A midbrain or third ventricular tumor could cause vertical gaze palsy, extensor truncal rigidity, and pyramidal symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    incoordination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/1,111\">",
"     1,111",
"    </a>",
"    ]. A tumor of the pineal gland can produce the so-called Parinaud syndrome characterized by limited upgaze, sluggishly reactive and large pupils, and retraction nystagmus.",
"   </p>",
"   <p>",
"    Because patients with PSP usually exhibit early frontal lobe cognitive disturbances and sometimes frank dementia, they can be confused with cortical dementias such as frontotemporal dementia or Alzheimer disease. Pseudobulbar palsy, especially early in the disease course, can be confused with depression and other psychiatric illnesses. In cases of PSP with rapidly progressive moderate to severe dementia, Creutzfeldt-Jakob disease might be suspected.",
"   </p>",
"   <p>",
"    On rare occasions, patients who manifest classic features of PSP, including eye movement abnormalities, early falls, and parkinsonism, will be found to have the pathology of other disorders including multiple system atrophy, corticobasal degeneration, Alzheimer disease, and idiopathic Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90507654\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease progression in PSP usually occurs fairly rapidly and relentlessly [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/90\">",
"     90",
"    </a>",
"    ]. Most patients become dependent for care within three or four years from presentation. The disorder culminates in death at a median of 6 to 12 years after the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/7,15,112-114\">",
"     7,15,112-114",
"    </a>",
"    ]. In addition, quality of life is significantly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the atypical (non-Richardson) forms of PSP, the duration of disease, delayed onset of falling, and later onset of eye movement abnormalities suggest a better prognosis compared with the Richardson form [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H90508451\">",
"     'Variant phenotypes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5944923\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no treatments that alter the natural history of disease in PSP and no drugs that provide significant symptomatic benefits as seen with levodopa in idiopathic Parkinson disease. However, several nonpharmacologic and pharmacologic supportive measures are available for the treatment of PSP. A multidisciplinary approach is essential.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietitians as well as speech and language therapists can help to manage dysphagia and dysarthria. Specific modalities for dysarthria include facial exercises, written communication, and a talking keyboard. Treatments for dysphagia include head posturing, dietary changes, and percutaneous gastrostomy in more advanced cases.",
"     </li>",
"     <li>",
"      Early occupational therapy is essential in promoting longer independence in performing activities of daily living. Mirror-prism lenses can allow patients with severe limitation of extraocular movements to read and feed themselves [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/116\">",
"       116",
"      </a>",
"      ]. Eyelid crutches, alone or in combination with botulinum toxin therapy, may be useful for eyelid opening apraxia and blepharospasm, which can be severe enough to render a PSP patient functionally blind [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/117\">",
"       117",
"      </a>",
"      ]. Decreased blink rate can be effectively treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , in addition to dark glasses to reduce photophobia.",
"     </li>",
"     <li>",
"      Physical therapy can provide symptomatic treatment for postural instability and falls, such as gait and balance training, in addition to advice on walking aides, such as weighted walkers and low-heel nonstick shoes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/118\">",
"       118",
"      </a>",
"      ]. The combination of frontal-lobe disturbance and postural instability results in significant difficulty in the management of patients with PSP, exposing them to even higher risks of falling. Freezing of gait can be improved by the use of walkers with lasers, visual cues, rhythmic cues, and arc turns.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20106031\">",
"    <span class=\"h2\">",
"     Support groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert nursing support and lay associations are invaluable for providing helpful information to caregivers and their families. Local, regional, and national associations can play an integral role to benefit lives of patients, family members, and caregivers. These groups include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Foundation for PSP | CBD and Related Brain Diseases (",
"      <a class=\"external\" href=\"file://www.psp.org/\">",
"       CurePSP",
"      </a>",
"      ) &ndash; North America",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.pspeur.org/\">",
"       The PSP Association",
"      </a>",
"      &ndash; Europe",
"     </li>",
"     <li>",
"      Worldwide Education and Awareness for Movement Disorders (",
"      <a class=\"external\" href=\"file://www.wemove.org/\">",
"       WE MOVE",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20106038\">",
"    <span class=\"h2\">",
"     Pharmacologic treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurotransmitter replacement strategies have",
"    <strong>",
"     not",
"    </strong>",
"    had a major therapeutic impact in PSP.",
"   </p>",
"   <p>",
"    The main role of levodopa in patients with suspected PSP is diagnostic; a poor or unsustained response to levodopa therapy is generally observed in patients with PSP and can help to distinguish PSP from idiopathic Parkinson disease. However, levodopa therapy may provide some degree of transient benefit as suggested by several small retrospective reports. One study found that 4 of 12 patients with postmortem-confirmed PSP showed a \"modest improvement\" while receiving levodopa with a peripheral decarboxylase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/119\">",
"     119",
"    </a>",
"    ]. The improvement was not sustained and resulted in adverse effects in more than half of the patients. In a later report of 15 cases of autopsy-confirmed PSP, nine showed some benefit to levodopa used in combination with other drugs, and five had some improvement on levodopa alone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/120\">",
"     120",
"    </a>",
"    ]. However, the benefit was generally minimal and was observed only in the early stages of the disease.",
"   </p>",
"   <p>",
"    A common side effect of levodopa in patients with PSP is visual hallucinations, although there have also been reports of dyskinesia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/119,121\">",
"     119,121",
"    </a>",
"    ], oromandibular dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/122\">",
"     122",
"    </a>",
"    ], and apraxia of eyelid opening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of other drugs have been tested for symptomatic treatment of PSP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Botulinum toxin injections can effectively treat various forms of focal dystonia and drooling",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"      can provide a transient therapeutic benefit in a minority of cases and can also help drooling and dyskinesia [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/119,125-127\">",
"       119,125-127",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       Zolpidem",
"      </a>",
"      administration was associated with improvement in 2 of 10 patients compared with placebo or levodopa [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/128\">",
"       128",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Idazoxan was associated with improved motor function in four of seven patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/129\">",
"       129",
"      </a>",
"      ], but this drug is not generally available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      has been assessed in a few patients with variable results [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/127,130,131\">",
"       127,130,131",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Methysergide was reported to improve dysphagia in an open label study of 12 patients with PSP [",
"      <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/132\">",
"       132",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20106590\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroconvulsive therapy, while helpful in some patients with idiopathic Parkinson disease, has been used in a small number of patients with PSP with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. Early anecdotal reports suggested negative results in patients with PSP who had neurosurgical treatments including pallidotomy and subthalamic or pallidal deep brain stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/124,135\">",
"     124,135",
"    </a>",
"    ]. In a case report, deep brain stimulation of the pedunculopontine nucleus was associated with modest benefit in a patient with PSP-parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/136\">",
"     136",
"    </a>",
"    ]. Approaches using this target are currently under further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93910182\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research into potential disease modifying therapies for PSP has focused on agents with tau-active properties [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/36\">",
"     36",
"    </a>",
"    ]. One approach involves agents such as tideglusib, which inhibits a key enzyme (glycogen synthase kinase 3 beta) that plays a role in the hyperphosphorylation of tau [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/137\">",
"     137",
"    </a>",
"    ]. Another approach involves the neuroprotective agent davunetide, which is thought to maintain microtubule function, reduce tau phosphorylation, and inhibit apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/138\">",
"     138",
"    </a>",
"    ]. Preliminary human trials are evaluating tideglusib [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/139\">",
"     139",
"    </a>",
"    ] and davunetide [",
"    <a class=\"abstract\" href=\"UTD.htm?25/30/26090/abstract/140\">",
"     140",
"    </a>",
"    ] for the treatment of PSP, and the results are awaited to see if they provide any promise for this difficult disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90508232\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As originally described, PSP is characterized by progressive supranuclear ophthalmoplegia, gait disorder and postural instability, dysarthria, dysphagia, rigidity, and frontal cognitive disturbance. PSP is now recognized to encompass a number of phenotypic variants. The two most common are Richardson syndrome (the classic form of PSP) and PSP-parkinsonism. (See",
"      <a class=\"local\" href=\"#H5944866\">",
"       'Historical background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mean age of onset for PSP is approximately 62 years. Virtually no cases of PSP have been reported in patients younger than age 40. (See",
"      <a class=\"local\" href=\"#H5944873\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the most common &ldquo;classic&rdquo; phenotype of PSP, known as Richardson syndrome, the most frequent initial feature of PSP is a disturbance of gait resulting in falls. Supranuclear ophthalmoparesis or plegia is the hallmark of PSP. Dysarthria, dysphagia, rigidity, frontal cognitive abnormalities, and sleep disturbances are additional common clinical features. PSP-parkinsonism is characterized by asymmetric onset of limb symptoms, tremor, and a moderate initial therapeutic response to levodopa. It may be confused with idiopathic Parkinson disease. (See",
"      <a class=\"local\" href=\"#H5944880\">",
"       'Clinical characteristics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H90508451\">",
"       'Variant phenotypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radiologic hummingbird sign (also called the penguin silhouette sign) results from the prominent midbrain atrophy in PSP with a relatively preserved pons, resembling a hummingbird or penguin in silhouette on midsagittal MRI of the brain (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78365 \" href=\"UTD.htm?42/3/43056\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H402998\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most consistent sites of microscopic findings in PSP are in the basal ganglia, particularly in the substantia nigra, subthalamic nucleus, cerebellum, and internal globus pallidus, in addition to the oculomotor complex, periaqueductal gray matter, superior colliculi, basis pontis, and dentate nucleus. Involvement of the cerebral cortex is also increasingly recognized. The histologic characteristics of PSP include neuronal loss, gliosis, and the presence of tau-positive filamentous inclusions in specific anatomic areas involving astrocytes, oligodendrocytes, and neurons (",
"      <a class=\"graphic graphic_picture graphicRef66637 \" href=\"UTD.htm?35/0/35849\">",
"       picture 1",
"      </a>",
"      ). Tau cytoplasmic inclusions in surviving neurons, known as globose neurofibrillary tangles, are classically described in PSP, but are not specific to PSP. (See",
"      <a class=\"local\" href=\"#H5944894\">",
"       'Pathology and pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PSP is based upon the clinical features. No laboratory or imaging studies are diagnostic. Neuropathologic examination remains the gold standard for its definitive diagnosis. The NINDS-SPSP criteria (",
"      <a class=\"graphic graphic_table graphicRef65437 \" href=\"UTD.htm?4/55/4989\">",
"       table 1",
"      </a>",
"      ) specify mandatory inclusion criteria for possible, probable, and definite PSP as well as mandatory exclusion criteria and supportive criteria for the diagnosis. (See",
"      <a class=\"local\" href=\"#H90507634\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H90507700\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of PSP by common clinical symptoms and signs is listed in the table (",
"      <a class=\"graphic graphic_table graphicRef53679 \" href=\"UTD.htm?38/45/39643\">",
"       table 2",
"      </a>",
"      ). The disorders that are the most difficult to differentiate from PSP are the other neurodegenerative parkinsonian disorders such as idiopathic Parkinson disease, corticobasal degeneration, multiple system atrophy, and dementia with Lewy bodies, as well as vascular parkinsonism. (See",
"      <a class=\"local\" href=\"#H5944901\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease progression in PSP usually occurs fairly rapidly and relentlessly compared with Parkinson disease. Most patients become dependent for care within three or four years from presentation. The disorder culminates in death at a median of 6 to 12 years after the diagnosis. (See",
"      <a class=\"local\" href=\"#H90507654\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no treatments that alter the natural history of disease in PSP and no drugs that provide significant symptomatic benefits as seen with levodopa in idiopathic Parkinson disease. However, several nonpharmacologic and pharmacologic supportive measures are available for the treatment of PSP. A multidisciplinary approach is essential. (See",
"      <a class=\"local\" href=\"#H5944923\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/1\">",
"      STEELE JC, RICHARDSON JC, OLSZEWSKI J. PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol 1964; 10:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/2\">",
"      Kristensen MO. Progressive supranuclear palsy--20 years later. Acta Neurol Scand 1985; 71:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/3\">",
"      Golbe LI. Progressive Supranuclear Palsy. Curr Treat Options Neurol 2001; 3:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/4\">",
"      Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/5\">",
"      Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/6\">",
"      Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/7\">",
"      Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/8\">",
"      Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/9\">",
"      Kawashima M, Miyake M, Kusumi M, et al. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord 2004; 19:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/10\">",
"      Mastaglia FL, Grainger K, Kee F, et al. Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome) clinical and electrophysiological observations in eleven cases. Proc Aust Assoc Neurol 1973; 10:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/11\">",
"      Radhakrishnan K, Thacker AK, Maloo JC, et al. Descriptive epidemiology of some rare neurological diseases in Benghazi, Libya. Neuroepidemiology 1988; 7:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/12\">",
"      Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/13\">",
"      Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/14\">",
"      Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Mov Disord 2011; 26:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/15\">",
"      Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986; 36:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/16\">",
"      Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/17\">",
"      De Bruin VM, Lees AJ. Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases. Mov Disord 1994; 9:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/18\">",
"      Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996; 46:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/19\">",
"      Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology 1998; 50:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/20\">",
"      Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy. Clinico-pathological data in 10 cases. Brain 1996; 119 ( Pt 4):1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/21\">",
"      Frasca J, Blumbergs PC, Henschke P, Burns RJ. A clinical and pathological study of progressive supranuclear palsy. Clin Exp Neurol 1991; 28:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/22\">",
"      Baba Y, Putzke JD, Whaley NR, et al. Progressive supranuclear palsy: phenotypic sex differences in a clinical cohort. Mov Disord 2006; 21:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/23\">",
"      Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. Risk factors for progressive supranuclear palsy. Neurology 1988; 38:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/24\">",
"      Golbe LI, Rubin RS, Cody RP, et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology 1996; 47:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/25\">",
"      McCrank E. PSP risk factors. Neurology 1990; 40:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/26\">",
"      McCrank E, Rabheru K. Four cases of progressive supranuclear palsy in patients exposed to organic solvents. Can J Psychiatry 1989; 34:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/27\">",
"      de Y&eacute;benes JG, Sarasa JL, Daniel SE, Lees AJ. Familial progressive supranuclear palsy. Description of a pedigree and review of the literature. Brain 1995; 118 ( Pt 5):1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/28\">",
"      Rojo A, Pernaute RS, Font&aacute;n A, et al. Clinical genetics of familial progressive supranuclear palsy. Brain 1999; 122 ( Pt 7):1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/29\">",
"      Donker Kaat L, Boon AJ, Azmani A, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology 2009; 73:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/30\">",
"      H&ouml;glinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/31\">",
"      Pittman AM, Myers AJ, Duckworth J, et al. The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet 2004; 13:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/32\">",
"      Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005; 14:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/33\">",
"      Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 2005; 42:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/34\">",
"      Zabetian CP, Hutter CM, Factor SA, et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol 2007; 62:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/35\">",
"      Baker KB, Montgomery EB Jr. Performance on the PD test battery by relatives of patients with progressive supranuclear palsy. Neurology 2001; 56:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/36\">",
"      Boeve BF. Progressive supranuclear palsy. Parkinsonism Relat Disord 2012; 18 Suppl 1:S192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/37\">",
"      Litvan I. Update on progressive supranuclear palsy. Curr Neurol Neurosci Rep 2004; 4:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/38\">",
"      Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/39\">",
"      Troost BT, Daroff RB. The ocular motor defects in progressive supranuclear palsy. Ann Neurol 1977; 2:397.",
"     </a>",
"    </li>",
"    <li>",
"     Broderick M, Riley DE. Parkinson's-plus disorders. In: Parkinson's disease: Diagnosis and clinical management, 2nd ed, Factor SA, Weiner WJ (Eds), Demos Medical Publishing, New York 2008. p.727.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/41\">",
"      Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1997; 62:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/42\">",
"      Rafal RD, Friedman JH. Limb dystonia in progressive supranuclear palsy. Neurology 1987; 37:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/43\">",
"      Dubois B, Pillon B, Legault F, et al. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol 1988; 45:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/44\">",
"      Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease. Neurology 1986; 36:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/45\">",
"      Golbe LI, Boeve BF, Keegan BM, Parisi JE. An 81-year-old man with imbalance and memory impairment. Neurology 2007; 68:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/46\">",
"      Brown RG, Lacomblez L, Landwehrmeyer BG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010; 133:2382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/47\">",
"      Pharr V, Uttl B, Stark M, et al. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2001; 56:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/48\">",
"      Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996; 47:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/49\">",
"      Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/50\">",
"      Fukui T, Lee E, Hosoda H, Okita K. Obsessive-compulsive behavior as a symptom of dementia in progressive supranuclear palsy. Dement Geriatr Cogn Disord 2010; 30:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/51\">",
"      Aldrich MS, Foster NL, White RF, et al. Sleep abnormalities in progressive supranuclear palsy. Ann Neurol 1989; 25:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/52\">",
"      Boeve BF, Silber MH, Parisi JE, et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003; 61:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/53\">",
"      Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/54\">",
"      Schofield EC, Hodges JR, Macdonald V, et al. Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov Disord 2011; 26:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/55\">",
"      Mizusawa H, Mochizuki A, Ohkoshi N, et al. Progressive supranuclear palsy presenting with pure akinesia. Adv Neurol 1993; 60:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/56\">",
"      Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/57\">",
"      Riley DE, Fogt N, Leigh RJ. The syndrome of 'pure akinesia' and its relationship to progressive supranuclear palsy. Neurology 1994; 44:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/58\">",
"      Matsuo H, Takashima H, Kishikawa M, et al. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1991; 54:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/59\">",
"      Facheris MF, Maniak S, Scaravilli F, et al. Pure akinesia as initial presentation of PSP: a clinicopathological study. Parkinsonism Relat Disord 2008; 14:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/60\">",
"      Factor SA, Jennings DL, Molho ES, Marek KL. The natural history of the syndrome of primary progressive freezing gait. Arch Neurol 2002; 59:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/61\">",
"      Compta Y, Valldeoriola F, Tolosa E, et al. Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord 2007; 22:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/62\">",
"      Factor SA, Higgins DS, Qian J. Primary progressive freezing gait: a syndrome with many causes. Neurology 2006; 66:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/63\">",
"      Cordato NJ, Halliday GM, McCann H, et al. Corticobasal syndrome with tau pathology. Mov Disord 2001; 16:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/64\">",
"      Boeve B, Dickson D, Duffy J, et al. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol 2003; 49:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/65\">",
"      Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 2008; 21:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/66\">",
"      Rohrer JD, Paviour D, Bronstein AM, et al. Progressive supranuclear palsy syndrome presenting as progressive nonfluent aphasia: a neuropsychological and neuroimaging analysis. Mov Disord 2010; 25:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/67\">",
"      Ahmed Z, Josephs KA, Gonzalez J, et al. Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain 2008; 131:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/68\">",
"      Graber JJ, Staudinger R. Teaching NeuroImages: \"Penguin\" or \"hummingbird\" sign and midbrain atrophy in progressive supranuclear palsy. Neurology 2009; 72:e81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/69\">",
"      Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003; 210:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/70\">",
"      Shukla R, Sinha M, Kumar R, Singh D. 'Hummingbird' sign in progressive supranuclear palsy. Ann Indian Acad Neurol 2009; 12:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/71\">",
"      Tsuboi Y, Slowinski J, Josephs KA, et al. Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2003; 60:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/72\">",
"      Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/73\">",
"      Scaravilli T, Pramstaller PP, Salerno A, et al. Neuronal loss in Onuf's nucleus in three patients with progressive supranuclear palsy. Ann Neurol 2000; 48:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/74\">",
"      Takahashi M, Weidenheim KM, Dickson DW, Ksiezak-Reding H. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol 2002; 61:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/75\">",
"      Feany MB, Dickson DW. Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 1996; 40:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/76\">",
"      Gearing M, Olson DA, Watts RL, Mirra SS. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994; 44:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/77\">",
"      Scaravilli T, Tolosa E, Ferrer I. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting. Mov Disord 2005; 20 Suppl 12:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/78\">",
"      Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001; 56:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/79\">",
"      Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/80\">",
"      Higgins JJ, Golbe LI, De Biase A, et al. An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. Neurology 2000; 55:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/81\">",
"      Kasashima S, Oda Y. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2003; 105:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/82\">",
"      Warren NM, Piggott MA, Lees AJ, Burn DJ. The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2007; 78:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/83\">",
"      Pascual J, Berciano J, Grijalba B, et al. Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study. Ann Neurol 1992; 32:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/84\">",
"      Pierot L, Desnos C, Blin J, et al. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 1988; 86:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/85\">",
"      Juncos JL, Hirsch EC, Malessa S, et al. Mesencephalic cholinergic nuclei in progressive supranuclear palsy. Neurology 1991; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/86\">",
"      Zweig RM, Whitehouse PJ, Casanova MF, et al. Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987; 22:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/87\">",
"      Suzuki M, Desmond TJ, Albin RL, Frey KA. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology 2002; 58:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/88\">",
"      Holemans S, Javoy F, Agid Y, et al. [3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy. Brain Res 1991; 565:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/89\">",
"      Levy R, Ruberg M, Herrero MT, et al. Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. Neurology 1995; 45:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/90\">",
"      Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/91\">",
"      Mendell JR, Engel WK, Chase TN. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. Lancet 1970; 1:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/92\">",
"      Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001; 183:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/93\">",
"      Borroni B, Malinverno M, Gardoni F, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008; 71:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/94\">",
"      Warmuth-Metz M, Naumann M, Csoti I, Solymosi L. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 2001; 58:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/95\">",
"      Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005; 64:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/96\">",
"      Looi JC, Macfarlane MD, Walterfang M, et al. Morphometric analysis of subcortical structures in progressive supranuclear palsy: In vivo evidence of neostriatal and mesencephalic atrophy. Psychiatry Res 2011; 194:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/97\">",
"      Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/98\">",
"      Morelli M, Arabia G, Salsone M, et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Mov Disord 2011; 26:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/99\">",
"      Morelli M, Arabia G, Novellino F, et al. MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study. Neurology 2011; 77:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/100\">",
"      Karimi M, Perlmutter JS. MRI measures predict progressive supranuclear palsy: clinically useful? Neurology 2011; 77:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/101\">",
"      Mishina M, Ishii K, Mitani K, et al. Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy. Acta Neurol Scand 2004; 110:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/102\">",
"      Blin J, Baron JC, Dubois B, et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol 1990; 47:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/103\">",
"      Foster NL, Gilman S, Berent S, et al. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988; 24:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/104\">",
"      Goffinet AM, De Volder AG, Gillain C, et al. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol 1989; 25:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/105\">",
"      Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/106\">",
"      Valls-Sol&eacute; J. Neurophysiological characterization of parkinsonian syndromes. Neurophysiol Clin 2000; 30:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/107\">",
"      Rivaud-P&eacute;choux S, Vidailhet M, Gallouedec G, et al. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000; 54:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/108\">",
"      Murphy MA, Friedman JH, Tetrud JW, Factor SA. Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases. J Clin Neurosci 2005; 12:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/109\">",
"      Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology 1987; 37:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/110\">",
"      Weiner WJ. A differential diagnosis of Parkinsonism. Rev Neurol Dis 2005; 2:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/111\">",
"      David NJ, Mackey EA, Smith JL. Further observations in progressive supranuclear palsy. Neurology 1968; 18:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/112\">",
"      Testa D, Monza D, Ferrarini M, et al. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 2001; 22:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/113\">",
"      Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/114\">",
"      O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008; 131:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/115\">",
"      Winter Y, Spottke AE, Stamelou M, et al. Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis 2011; 8:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/116\">",
"      Burn DJ, Warren NM. Toward future therapies in progressive supranuclear palsy. Mov Disord 2005; 20 Suppl 12:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/117\">",
"      Krack P, Marion MH. \"Apraxia of lid opening,\" a focal eyelid dystonia: clinical study of 32 patients. Mov Disord 1994; 9:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/118\">",
"      Sosner J, Wall GC, Sznajder J. Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients. Arch Phys Med Rehabil 1993; 74:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/119\">",
"      Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998; 55:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/120\">",
"      Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002; 17:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/121\">",
"      Rajput A, Rajput AH. Progressive supranuclear palsy: clinical features, pathophysiology and management. Drugs Aging 2001; 18:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/122\">",
"      Tan EK, Chan LL, Wong MC. Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Clin Neurol Neurosurg 2003; 105:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/123\">",
"      Defazio G, De Mari M, De Salvia R, et al. \"Apraxia of eyelid opening\" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report. Clin Neuropharmacol 1999; 22:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/124\">",
"      Lang AE. Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2005; 20 Suppl 12:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/125\">",
"      Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 1997; 3:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/126\">",
"      Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 1983; 13:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/127\">",
"      Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993; 16:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/128\">",
"      Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/129\">",
"      Ghika J, Tennis M, Hoffman E, et al. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991; 41:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/130\">",
"      Engel PA. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 1996; 44:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/131\">",
"      Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985; 35:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/132\">",
"      Duncombe AS, Lees AJ. Methysergide in progressive supranuclear palsy. Neurology 1985; 35:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/133\">",
"      Barclay CL, Duff J, Sandor P, Lang AE. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 1996; 46:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/134\">",
"      Hauser RA, Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov Disord 1994; 9:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/135\">",
"      Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 2005; 62:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/136\">",
"      Brusa L, Iani C, Ceravolo R, et al. Implantation of the nucleus tegmenti pedunculopontini in a PSP-P patient: safe procedure, modest benefits. Mov Disord 2009; 24:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/137\">",
"      Dom&iacute;nguez JM, Fuertes A, Orozco L, et al. Evidence for irreversible inhibition of glycogen synthase kinase-3&beta; by tideglusib. J Biol Chem 2012; 287:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/30/26090/abstract/138\">",
"      Gold M, Lorenzl S, Stewart AJ, et al. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 2012; 8:85.",
"     </a>",
"    </li>",
"    <li>",
"     Safety, tolerability, and efficacy of two different oral doses of NP031112 versus placebo in the treatment of patients with mild-to-moderate progressive supranuclear palsy (Tauros). file://clinicaltrials.gov/ct2/show/NCT01049399 (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     Study to evaluate the safety and efficacy of davunetide for the treatment of progressive supranuclear palsy. file://clinicaltrials.gov/ct2/show/NCT01049399 (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14136 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-118.97.94.19-03632C4B59-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26090=[""].join("\n");
var outline_f25_30_26090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90508232\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90507646\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5944866\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5944873\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90508640\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H439178170\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5944880\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3595923\">",
"      Postural instability and falls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H402970\">",
"      Oculomotor findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H402977\">",
"      Motor involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H402984\">",
"      Cognitive and behavioral abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H402991\">",
"      Sleep disturbances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90508451\">",
"      Variant phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H402998\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5944894\">",
"      PATHOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90507634\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90507700\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20105117\">",
"      Potential disease markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5944901\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90507654\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5944923\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20106031\">",
"      Support groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20106038\">",
"      Pharmacologic treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20106590\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93910182\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90508232\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14136|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/3/43056\" title=\"diagnostic image 1\">",
"      Hummingbird sign in PSP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14136|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/0/35849\" title=\"picture 1\">",
"      Microscopic findings of PSP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/55/4989\" title=\"table 1\">",
"      Diagnostic criteria for PSP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/45/39643\" title=\"table 2\">",
"      Differential diagnosis of PSP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5354?source=related_link\">",
"      Corticobasal degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29465?source=related_link\">",
"      Multiple system atrophy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_30_26091="ACR RA response criteria";
var content_f25_30_26091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Rheumatology 20 percent improvement criteria (ACR20)",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        At least 20 percent&nbsp;improvement in",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Swollen joint counts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. tender joint count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        and&nbsp;three of the following&nbsp;five variables:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Patient assessed global disease activity (eg, by VAS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Evaluator assessed global disease activity (eg, by VAS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Patient pain assessment (eg, by VAS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Functional disability (eg, by HAQ)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Acute phase response (ESR or CRP)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A 50 percent&nbsp;and 70 percent&nbsp;ACR response (ACR50 and ACR70, respectively)&nbsp;represents respective improvement of at least 50 perecent&nbsp;or at least 70 percent.",
"    <sup>",
"     [2]",
"    </sup>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Felson, DT, Anderson, JJ, Boers, M, Bombardier, C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727.",
"       </li>",
"       <li>",
"        Felson, DT, Anderson, JJ, Lange, ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?. Arthritis Rheum 1998; 41:1564.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26091=[""].join("\n");
var outline_f25_30_26091=null;
var title_f25_30_26092="Low-potassium foods Basic PI";
var content_f25_30_26092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some foods that are low in potassium",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Fruits",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vegetables",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apple juice",
"       </td>",
"       <td>",
"        Alfalfa sprouts",
"       </td>",
"       <td>",
"        Almonds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apples and applesauce",
"       </td>",
"       <td>",
"        Asparagus",
"       </td>",
"       <td>",
"        Cashews",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blackberries",
"       </td>",
"       <td>",
"        Cabbage (cooked)",
"       </td>",
"       <td>",
"        Chicken",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blueberries",
"       </td>",
"       <td>",
"        Carrots (cooked)",
"       </td>",
"       <td>",
"        Eggs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cherries",
"       </td>",
"       <td>",
"        Cauliflower",
"       </td>",
"       <td>",
"        Flax seed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranberries",
"       </td>",
"       <td>",
"        Celery",
"       </td>",
"       <td>",
"        Peanuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grapefruit",
"       </td>",
"       <td>",
"        Corn",
"       </td>",
"       <td>",
"        Pumpkin seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grapes and grape juice",
"       </td>",
"       <td>",
"        Cucumber",
"       </td>",
"       <td>",
"        Shrimp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peaches",
"       </td>",
"       <td>",
"        Eggplant",
"       </td>",
"       <td>",
"        Sunflower seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pears",
"       </td>",
"       <td>",
"        Green beans",
"       </td>",
"       <td>",
"        Tuna",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pineapple",
"       </td>",
"       <td>",
"        Green peas",
"       </td>",
"       <td>",
"        Turkey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plums",
"       </td>",
"       <td>",
"        Green peppers",
"       </td>",
"       <td>",
"        Walnuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raspberries",
"       </td>",
"       <td>",
"        Kale",
"       </td>",
"       <td rowspan=\"11\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strawberries",
"       </td>",
"       <td>",
"        Lettuce",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Watermelon",
"       </td>",
"       <td>",
"        Okra",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Onions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhubarb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water chestnuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wax beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yellow squash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zucchini",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26092=[""].join("\n");
var outline_f25_30_26092=null;
var title_f25_30_26093="Comparison TB clinical features";
var content_f25_30_26093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of clinical features of tuberculosis from the literature",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Current study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arrango",
"       </td>",
"       <td class=\"subtitle1\">",
"        MacGregor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elliott",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gnaore",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Year of study",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        1993",
"       </td>",
"       <td class=\"centered\">",
"        1970-1971",
"       </td>",
"       <td class=\"centered\">",
"        1971-1972",
"       </td>",
"       <td class=\"centered\">",
"        1989",
"       </td>",
"       <td class=\"centered\">",
"        1989-1990",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Country",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        US (Los Angeles)",
"       </td>",
"       <td class=\"centered\">",
"        US (San Francisco)",
"       </td>",
"       <td class=\"centered\">",
"        US (Philadelphia)",
"       </td>",
"       <td class=\"centered\">",
"        Zambia",
"       </td>",
"       <td class=\"centered\">",
"        Ivory Coast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Focus of study",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Population-based",
"       </td>",
"       <td class=\"centered\">",
"        Urban hospital",
"       </td>",
"       <td class=\"centered\">",
"        Postsanitory tuberculosis",
"       </td>",
"       <td class=\"centered\">",
"        HIV",
"       </td>",
"       <td class=\"centered\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No. of patients",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        313",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        41",
"       </td>",
"       <td class=\"centered\">",
"        249",
"       </td>",
"       <td class=\"centered\">",
"        4504",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         HIV",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        12.1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        73.1",
"       </td>",
"       <td class=\"centered\">",
"        43.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cough",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        48.2*",
"       </td>",
"       <td class=\"centered\">",
"        42",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        61.7 (67.8)",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        79.9 (80.7)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fever",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        29.4*",
"       </td>",
"       <td class=\"centered\">",
"        37",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        44",
"       </td>",
"       <td class=\"centered\">",
"        36.7 (23.5)",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        69.2 (67.9)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Weight loss",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        44.5",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        74.3 (70.3)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Hemoptysis",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        20.9",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Lymphadenopathy",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        13.2",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        51.4 (20.1)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Diarrhea",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        12.1",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        8.1 (5.2)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Data are percentages unless otherwise indicated.",
"    <div class=\"footnotes\">",
"     * Symptoms lasting at least two weeks.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Fever not distinguished from sweats.",
"     <br/>",
"     &Delta; Numbers in parentheses represent symptoms normalized for 12.1 percent HIV rate.",
"     <br/>",
"     &loz; Symptoms lasting at least one month.",
"    </div>",
"    <div class=\"reference\">",
"     From: Miller LG, Asch SM, Yu EI, et al. A population-based survey of tuberculosis symptoms: How atypical are atypical presentations? Clin Infect Dis 2000; 30:293. By permission of the Infectious Diseases Society of America. Copyright &copy; 2000 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26093=[""].join("\n");
var outline_f25_30_26093=null;
var title_f25_30_26094="MALDI-TOF MS human lung tumor";
var content_f25_30_26094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proteomic spectrum of human lung tumor tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Representative matrix-assisted laser desorption ionization time-of flight mass spectrography (MALDI-TOF MS) protein spectrum obtained directly from human lung tumor tissue.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of D Carbone, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26094=[""].join("\n");
var outline_f25_30_26094=null;
var title_f25_30_26095="Mallet finger deformity";
var content_f25_30_26095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resisting the action of the extensor profundus tendon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The affected finger is grasped with one hand and the finger of the second hand is placed atop the distal phalanges. The patient is asked to actively extend the DIP joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_30_26095=[""].join("\n");
var outline_f25_30_26095=null;
